Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

 
   volgende >>
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             2413 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 AD2 DYNAMICS OF SWITCHING, ADHERENCE, AND PERSISTENCE OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS USE: AN AUSTRALIAN PERSPECTIVE Ofori-Asenso, R.
22 S3 p. S403
 artikel
2 AD4 ESTIMATING THE RELIABILITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND IDENTIFYING THE REASONS FOR NON-ADHERENCE Unni, E.
22 S3 p. S403-S404
 artikel
3 AD3 ORAL ANTICOAGULANT PRESCRIPTION TRENDS, PROFILE USE AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH ATRIAL FIBRILLATION Perreault, S.
22 S3 p. S403
 artikel
4 AD1 PERSISTENCE OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL LONGITUDINAL OBSERVATIONAL POPULATION STUDY IN SWEDEN Stelmaszuk-Zadykowicz, N.M.
22 S3 p. S403
 artikel
5 AI3 DEVELOPMENT OF A DECISION-AID FOR PATIENTS WITH DEPRESSION CONSIDERING TREATMENT OPTIONS: PREDICTION OF TREATMENT RESPONSE USING A DATA-DRIVEN APPROACH Kan, K.
22 S3 p. S404
 artikel
6 AI4 GENERAL PAIRWISE COMPARISONS TO SUPPORT QUANTITATIVE MULTIPLE CRITERIA DECISION ANALYSIS Chiem, J.C.
22 S3 p. S404-S405
 artikel
7 AI2 GEO-SPATIAL RISK ASSESSMENT OF ASTHMA HEALTH RESOURCE USE AT THE MUNICIPAL LEVEL IN THE GREATER HELSINKI METROPOLITAN AREA OF FINLAND Navaratnam, P.
22 S3 p. S404
 artikel
8 AI1 PREDICTORS OF HIGH HEALTHCARE UTILISERS AMONG PATIENTS WITH CHRONIC HYPOPARATHYROIDISM €“ APPLICATION OF MACHINE LEARNING METHODOLOGY Chen, K.
22 S3 p. S404
 artikel
9 CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA Guan, X.
22 S3 p. S405-S406
 artikel
10 CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE Cariou, C.
22 S3 p. S405
 artikel
11 CC1 COST-EFFECTIVENESS OF SCREENING AND TREATING CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA EARLY IN LIFE FROM A DUTCH HEALTHCARE PERSPECTIVE Ademi, Z.
22 S3 p. S405
 artikel
12 CC2 ECONOMIC ASSESSMENT OF A HIGH DOSE VERSUS A STANDARD DOSE INFLUENZA VACCINE IN THE US VETERAN POPULATION: ESTIMATING THE IMPACT ON HOSPITALIZATION COST FOR CARDIOVASCULAR AND RESPIRATORY DISEASE van Aalst, R.
22 S3 p. S405
 artikel
13 CE3 COMPARATIVE EFFECTIVENESS AMONG SINGLE AGENT CHEMOTHERAPEUTICS IN THE TREATMENT OF TNBC USING TIME TO NEXT TREATMENT AS A SURROGATE FOR EFFICACY Feinberg, B.A.
22 S3 p. S406
 artikel
14 CE4 COMPARISON OF NETWORK META-ANALYSIS (NMA) USING THE BAYESIAN AND FREQUENTIST APPROACH: CONCRETE EXAMPLE ON THE BASIS OF A PUBLISHED NMA IN RELAPSING REMITTING MULTIPLE SCLEROSIS AND PLAQUE PSORIASIS Dasari, A.
22 S3 p. S406
 artikel
15 CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE INADEQUATE RESPONDERS TO USTEKINUMAB: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) Borg, E.
22 S3 p. S406
 artikel
16 CE1 EVALUATION OF THE EVOLVING TREATMENT LANDSCAPE IN EARLY-STAGE/LOCALLY-ADVANCED NON-SMALL CELL LUNG CANCER (ES/LA-NSCLC): A FORWARD-LOOKING NETWORK META-ANALYSIS (NMA) FEASIBILITY STUDY Rizzo, M.
22 S3 p. S406
 artikel
17 CL1 ASSOCIATION BETWEEN DIABETES MEDICATION USE AND CARDIOVASCULAR EVENTS AMONG TYPE 2 DIABETES PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE: A NATIONWIDE COHORT STUDY. Chang, H.C.
22 S3 p. S407
 artikel
18 CL4 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF THE EFFICACY AND TOLERABILITY OF APALUTAMIDE AND DAROLUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) Chowdhury, S.
22 S3 p. S407
 artikel
19 CL2 SYSTEMATIC REVIEW AND METANALYSIS ON THE IMPACT OF MULTI-DRUG RESISTANT BACTERIA ON ECONOMIC AND CLINICAL OUTCOMES OF HEALTHCARE ACQUIRED INFECTIONS Serra-Burriel, M.
22 S3 p. S407
 artikel
20 CL3 THE ASSOCIATION BETWEEN TREATMENT INTENSITY AND ADHERENCE TO LIPID-LOWERING THERAPIES AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PRIMARY AND SECONDARY CARE: A SWEDISH REGISTRY-BASED STUDY Leosdottir, M.
22 S3 p. S407
 artikel
21 CP3 DEVELOPING PROCESSES AND METHODS FOR A EUROPEAN COLLABORATION ON HTA: ACHIEVEMENTS, CHALLENGES AND LESSONS LEARNT Fathollah-Nejad, R.
22 S3 p. S408
 artikel
22 CP2 DO SOCIAL VALUES AND INSTITUTIONAL CONTEXT IMPACT THE USE OF ECONOMIC EVALUATION IN PRIORITY SETTING: EMPIRICAL EVIDENCE FROM OECD COUNTRIES Torbica, A.
22 S3 p. S408
 artikel
23 CP4 META-ANALYSIS POWERED BY ARTIFICIAL INTELLIGENCE Joshi, S.
22 S3 p. S408
 artikel
24 CP1 THE IMPACT OF USING AGGREGATE DATA FOR MULTISTATE MODELLING PURPOSES IN ECONOMIC EVALUATIONS Wigfield, P.
22 S3 p. S407-S408
 artikel
25 CV1 DIABETES TREATMENT IN DENMARK: HOSPITAL- VS. GP-MONITORING Pulleyblank, R.
22 S3 p. S408
 artikel
26 CV4 HOSPITALIZED WITH STROKE AT THE WEEKEND: ARE THERE HIGHER RISK OF EARLY DEATH AND HIGHER COSTS? Ghiani, M.
22 S3 p. S409
 artikel
27 CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS Neeser, K.
22 S3 p. S409
 artikel
28 CV2 NATIONAL SAVINGS FROM TELEHEALTH CARE IN HEART FAILURE RESULTS FROM THE DANISH TELECARE NORTH TRIAL Ehlers, L.
22 S3 p. S409
 artikel
29 HT1 DOES HIV COINFECTION AFFECT HCV REIMBURSEMENT DECISIONS? Gizaw, N.
22 S3 p. S409
 artikel
30 HT4 INCLUSION OF PATIENT INPUT IN VALUE AND HEALTH TECHNOLOGY ASSESSMENT Desai, B.
22 S3 p. S410
 artikel
31 HT2 IS THERE POTENTIAL FOR JOINT HEALTH TECHNOLOGY ASSESSMENT (HTA) IN EUROPE? AN EVALUATION OF EUNETHTA JOINT CLINICAL ASSESSMENTS VS. NATIONAL APPRAISALS IN ONCOLOGY Jose, R.
22 S3 p. S409-S410
 artikel
32 HT3 WHAT INFLUENCES THE PROBABILITY TO BE SUCCESSFUL IN AN ONCOLOGY HTA? AN ANALYSIS OF ONCOLOGY HTA DECISIONS IN GERMANY, SPAIN AND THE UK Hardtstock, F.
22 S3 p. S410
 artikel
33 IN1 BREAK THE BRAKES: BRAKES AND INCITEMENTS TO INFLUENZA VACCINATION, A MEDICAL RESIDENTS-CENTERED SURVEY Colrat, F.
22 S3 p. S410
 artikel
34 IN2 IMPACT OF TESTING & RAPID INITIATION ON HIV INCIDENCE IN FRANCE: RESULTS OF A TRANSMISSION MODEL Pialoux, G.
22 S3 p. S410
 artikel
35 IN3 THE HEALTH SYSTEM BURDEN OF SELECTED VACCINE-PREVENTABLE ILLNESSES ON SECONDARY CARE IN ENGLAND: A FIVE-YEAR STUDY USING AN ADMINISTRATIVE HEALTHCARE DATASET Rabe, A.P.
22 S3 p. S410-S411
 artikel
36 MT4 COST ANALYSIS OF INTEGRATED VERSUS CONVENTIONAL OPERATING ROOMS Risør, B.
22 S3 p. S411
 artikel
37 MT1 LONG BONE FRACTURES: OVERVIEW OF SURGICAL APPROACHES BY FRACTURE TYPES AND PATIENT PROFILE Chitnis, A.S.
22 S3 p. S411
 artikel
38 MT3 OUTCOMES AND HOSPITAL UTILIZATION OF SLEEP APNEA PATIENTS TREATED WITH POSITIVE AIRWAY PRESSURE DURING AND AFTER ONSET OF HEART FAILURE Huang, F.
22 S3 p. S411
 artikel
39 MT2 UNDERSTANDING POTENTIAL CAPACITY CONSTRAINTS RESTRICTING TIME-TO-DIAGNOSIS IN A MULTI-DISCIPLINARY DIAGNOSTIC CENTRE (MDC) FOR PEOPLE WITH NON-SPECIFIC SYMPTOMS OF CANCER: A DISCRETE EVENT SIMULATION Jones, C.
22 S3 p. S411
 artikel
40 ND1 HEALTHCARE RESOURCE USE IN HEADACHE SPECIALIZED CENTERS TO MANAGE MIGRAINE PORTUGUESE PATIENTS WHO HAVE FAILED PREVIOUS PROPHYLACTIC TREATMENT Silva, C.
22 S3 p. S412
 artikel
41 ND3 SHORT- AND LONG-TERM DISABILITY BURDEN AMONG EMPLOYED PATIENTS RECEIVING DISEASE-MODIFYING TREATMENT FOR MULTIPLE SCLEROSIS Bonafede, M.
22 S3 p. S412
 artikel
42 ND2 THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS ON WORK-RELATED OUTCOMES: A MIXED METHODS APPROACH Sikora Kessler, J.
22 S3 p. S412
 artikel
43 ND4 WHO BENEFITS MOST FROM COLLABORATIVE DEMENTIA CARE? A POST-HOC SUBGROUP COST-EFFECTIVENESS ANALYSIS Rädke, A.
22 S3 p. S412
 artikel
44 ON8 CHEMOTHERAPY INDUCED NAUSEA VOMITING: VALIDATION OF RISK SCORING ALGORITHM IN PATIENTS WITH GYNECOLOGICAL AND GASTROINTESTINAL CANCERS D A,
22 S3 p. S414
 artikel
45 ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES Stover, A.
22 S3 p. S413
 artikel
46 ON1 HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS RECEIVING TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD DATA FROM A LARGE HEALTHCARE PROVIDER Weil, C.
22 S3 p. S412-S413
 artikel
47 ON3 HOSPITAL COSTS BEFORE, DURING, AND AFTER DIAGNOSIS OF FIVE CANCER FORMS IN DENMARK DURING 2014 Green, A.
22 S3 p. S413
 artikel
48 ON6 IMPACT OF THE FOLLICULAR LYMPHOMA (FL) TREATMENT CONTINUUM ON A PATIENTS QUALITY OF LIFE (QOL) IN EUROPE (EU5) Häfliger, B.
22 S3 p. S413-S414
 artikel
49 ON4 THE ECONOMIC BURDEN OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A SOCIETAL PERSPECTIVE. Nazha, S.
22 S3 p. S413
 artikel
50 ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE Hashim, M.
22 S3 p. S414
 artikel
51 ON2 VARIATION IN METHODOLOGICAL APPROACH TO PRODUCTIVITY COST VALUATION: DISTRIBUTIONAL EFFECTS IN THE CASE OF PROSTATE CANCER Hanly, P.
22 S3 p. S413
 artikel
52 PAM14 ASSESSING THE NUTRITIONAL STATUS OF THE ELDERLY USING STANDARD STATUS SCALES Madarász, I.
22 S3 p. S417
 artikel
53 PAM5 A SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF INTERVENTIONS WITH A PERSONALIZED NUTRITION COMPONENT IN ADULTS Galekop, M.
22 S3 p. S415
 artikel
54 PAM6 BUDGET IMPACT ANALYSIS OF THE ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN OBESE PATIENTS IN ITALY Viti, R.
22 S3 p. S415-S416
 artikel
55 PAM9 COST AND NUTRITIONAL VALUE OF THREE ALTERNATIVE TEXTURE-MODIFIED DIETS FOR PATIENTS WITH SWALLOWING OR CHEWING DISORDERS: ABADIA STUDY Ballesteros, M.
22 S3 p. S416
 artikel
56 PAM1 COST-CONSEQUENCES ANALYSIS OF PAEDIATRIC TRIPLE-CHAMBER-BAGS (3CBS) IMPACT ON HOSPITAL RESOURCES AND CLINICAL OUTCOMES IN PRETERM NEONATES ACROSS BELGIUM, PORTUGAL, SPAIN AND THE UK Kriz, A.
22 S3 p. S414
 artikel
57 PAM2 COST SAVINGS ASSOCIATED WITH COMPREHENSIVE HOSPITAL-BASED NUTRITION PROGRAMS FOR MALNOURISHED COLOMBIAN PATIENTS Buitrago, G.
22 S3 p. S414-S415
 artikel
58 PAM12 GENDER DIFFERENCES IN THE DIETARY HABITS OF SECONDARY SCHOOL STUDENTS Karácsony, I.
22 S3 p. S416-S417
 artikel
59 PAM4 HEALTHCARE UTILIZATION AND HOSPITALIZATION COSTS AMONG FRAIL AND AT-NUTRITIONAL RISK OR MALNOURISHED OLDER ADULTS Rodríguez-Sánchez, B.
22 S3 p. S415
 artikel
60 PAM13 IMPACT ON CARERS OF ADULT PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE Ballinger, R.
22 S3 p. S417
 artikel
61 PAM3 INDIVIDUALIZED NUTRITIONAL SUPPORT IN MEDICAL INPATIENTS RESULTS IN COST SAVINGS: ECONOMIC EVALUATION OF THE EFFORT TRIAL Schuetz, P.
22 S3 p. S415
 artikel
62 PAM11 NUTRITIONAL STATUS AND DIET RELATED RESULTS OF THE E-HARMONY PREVENTION PROGRAMME Breitenbach, Z.
22 S3 p. S416
 artikel
63 PAM15 PHOTOGRAPHIC FOOD DIARIES FOR NUTRITIONAL RESEARCH WITH CHILDREN AND HARD-TO-REACH POPULATIONS: A CASE STUDY EXPLORATION OF A NOVEL ASSESSMENT TOOL Brockfeld McClure, E.
22 S3 p. S417
 artikel
64 PAM16 PRESCRIBING PATTERNS OF VITAMIN D AND ANALOGUES IN A PRIVATE HEALTHCARE PATIENT POPULATION IN SOUTH AFRICA Morris-Paxton, A.
22 S3 p. S417
 artikel
65 PAM8 THE COMPARATIVE STUDY ON THE CONTENT OF ESTROGEN LEVELS IN WOMEN LIVED IN AREAS WITH HIGH SELENIUM AND AREAS WITH NORMAL SELENIUM Dong, Z.
22 S3 p. S416
 artikel
66 PAM10 THE EFFECT OF SUBNORMAL BODY MASS INDEX (BMI) ON HEALTHCARE RESOURCE USE IN PATIENTS UNDERGOING SURGERY: A CLINICAL DATABASE STUDY Richárd, B.
22 S3 p. S416
 artikel
67 PBI23 A COST ANALYSIS OF HEMOSTATIC SURGICAL RESOURCES ASSOCIATED WITH A NOVEL FIBRIN SEALANT COMPARED TO STANDARD OF CARE ACROSS SURGERY TYPES Danker III, W.
22 S3 p. S421
 artikel
68 PBI68 ADDED BENEFIT ASSESSMENT OF ATMPS IN GERMANY: DOES THE DATA BASIS MEET HTA REQUIREMENTS? Templin, C.
22 S3 p. S429-S430
 artikel
69 PBI4 A LANDSCAPE ASSESSMENT OF CELL AND GENE THERAPY REIMBURSEMENT IN THE UNITED STATES Hodgson, J.
22 S3 p. S418
 artikel
70 PBI42 ANALYSIS OF GENE AND CELL THERAPIES POLICIES IN EUROPEAN COUNTRIES Oguzhan Ergın, G.
22 S3 p. S424
 artikel
71 PBI66 ARE HTA AGENCIES BUYING INTO THE CAR-T HYPE? Kok, K.E.
22 S3 p. S429
 artikel
72 PBI88 ASSESSMENT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS ELIGIBLE FOR BIOLOGIC AGENTS Degli Esposti, L.
22 S3 p. S433-S434
 artikel
73 PBI73 ASSESSMENT OF THE FUTURE IMPACT OF BIOSIMILARS AND GENERICS FOR ULCERATIVE COLITIS IN THE US & EUROPE Smith, L.
22 S3 p. S430
 artikel
74 PBI65 ASSESSMENT OF WILLINGNESS TO PAY IN A RAPIDLY INCREASING BIOLOGICS MARKET FOR RESPIRATORY DISEASES Sefer, L.
22 S3 p. S429
 artikel
75 PBI52 ATMPS IN EUROPE: EXISTING CHALLENGES AND FUTURE DIRECTIONS Kamra, S.
22 S3 p. S426
 artikel
76 PBI84 BASELINE RHEUMATOID ARTHRITIS SEVERITY AMONG PATIENTS RECEIVING BIOLOGIC DMARDS: FINDINGS FROM A REAL-WORLD DATABASE Chan, C.
22 S3 p. S433
 artikel
77 PBI54 BIOSIMILAR AND ORIGINATOR INFLIXIMAB AND ETANERCEPT: INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS IN THE UK Moorkens, E.
22 S3 p. S427
 artikel
78 PBI37 BIOSIMILAR INTERCHANGEABILITY, SUBSTITUTION AND SWITCHING: AN OVERVIEW OF 5 EUROPEAN MEMBER STATES AND THE UNITED STATES Zapała, A.
22 S3 p. S423-S424
 artikel
79 PBI27 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE Gourzoulidis, G.
22 S3 p. S422
 artikel
80 PBI17 BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILAR RITUXIMAB AND TRASTUZUMAB COMPARED TO INTRAVENOUS AND SUBCUTANEOUS ORIGINATORS IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UK Jang, M.Y.
22 S3 p. S420
 artikel
81 PBI34 BUDGET IMPACT OF TRASTUZUMAB BIOSIMILARS FOR THE TREATMENT OF BREAST CANCER AND GASTRIC CANCER IN GREECE Solakidi, A.
22 S3 p. S423
 artikel
82 PBI78 CAR-T TREATMENTS: INSIGHTS FROM INITIAL HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN THE UK, GERMANY AND FRANCE Siak, S.
22 S3 p. S431
 artikel
83 PBI41 CHALLENGES AND OPPORTUNITIES FOR THE REIMBURSEMENT OF GENE THERAPIES - STAKEHOLDER INSIGHTS FROM GERMANY, SWEDEN AND THE UNITED KINGDOM Kolker, L.
22 S3 p. S424
 artikel
84 PBI10 CHALLENGES IN HEALTH ECONOMIC EVALUATION OF GENE REPLACEMENT THERAPIES: POTENTIAL SOLUTIONS FOR KEY METHODOLOGICAL ISSUES Thokagevistk, K.
22 S3 p. S419
 artikel
85 PBI93 CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN Stelmaszuk-Zadykowicz, N.M.
22 S3 p. S434
 artikel
86 PBI91 CHARACTERISTICS AND MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) PATIENTS IN A LARGE REPRESENTATIVE REAL WORLD COHORT Starzyk, K.
22 S3 p. S434
 artikel
87 PBI64 CHARACTERISTICS OF CLINICAL TRIALS DESIGNED TO ASSESS GENE THERAPIES Wojciechowski, P.
22 S3 p. S429
 artikel
88 PBI2 COMPARISON OF A NEW FIBRIN SEALANT TO CURRENT HEMOSTASIS METHODS IN PERIPHERAL VASCULAR SURGERY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Danker III, W.
22 S3 p. S418
 artikel
89 PBI31 COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS Dzik, M.
22 S3 p. S423
 artikel
90 PBI28 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE Gourzoulidis, G.
22 S3 p. S422
 artikel
91 PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE Gratacós, J.
22 S3 p. S419-S420
 artikel
92 PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE Monteagudo, I.
22 S3 p. S421
 artikel
93 PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL Peral, C.
22 S3 p. S421-S422
 artikel
94 PBI15 ECONOMIC BURDEN OF SICKLE CELL DISEASE: A TARGETED GLOBAL LITERATURE REVIEW Naik, A.
22 S3 p. S420
 artikel
95 PBI48 EQUALITY IN ACCESS TO DMARDS IN TURKEY Dilmac, E.
22 S3 p. S425-S426
 artikel
96 PBI18 ESTIMATION OF THE HEALTHCARE RESOURCE UTILIZATION (HCRU) COSTS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING TISAGENLECLEUCEL: A MICRO-COSTING STUDY IN THE UK AND FRANCE Yang, H.
22 S3 p. S420
 artikel
97 PBI76 EVOLUTION OF INTERVENTIONAL TRIALS FOR GENE THERAPIES Wojciechowski, P.
22 S3 p. S431
 artikel
98 PBI79 EXAMINING BIOLOGIC PRESCRIBING BEHAVIOURS AND ATTITUDES OF ATOPIC DERMATITIS SPECIALISTS IN EUROPE Robinson, P.
22 S3 p. S431-S432
 artikel
99 PBI71 EXPLORING UNCERTAINTIES AND SOLUTIONS ALLOWING PATIENT ACCESS TO CAR T-CELL THERAPIES: LEARNING TODAY HOW TO IMPROVE TOMORROW Borga, P.
22 S3 p. S430
 artikel
100 PBI55 FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US Lach, S.
22 S3 p. S427
 artikel
101 PBI19 GENE THERAPIES: HOW WILL INDICATION-BASED PRICING AFFECT PATIENT ACCESS AND COST-CONTAINMENT MECHANISMS FOR PAYERS? Grosvenor, A.
22 S3 p. S420
 artikel
102 PBI53 GENE THERAPY PREPAREDNESS IN EUROPE McAughey, E.
22 S3 p. S426-S427
 artikel
103 PBI83 GOLIMUMAB IMPROVES QUALITY OF LIFE AND OTHER PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN REAL-WORLD CONDITIONS Psaltis, D.
22 S3 p. S432-S433
 artikel
104 PBI35 HEALTH ECONOMICS MODELLING FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): A TARGETED LITERATURE REVIEW (LR) Agirrezabal, I.
22 S3 p. S423
 artikel
105 PBI63 IMPACT OF TOCILIZUMAB SUBCUTANEOUS INJECTION COMMERCIALIZATION ON PRACTICES IN THE PUBLIC HOSPITALS OF PARIS Leclerc, E.
22 S3 p. S428-S429
 artikel
106 PBI46 IMPLEMENTATION OF ADALIMUMAB BIOSIMILARS IN DENMARK Jensen, T.B.
22 S3 p. S425
 artikel
107 PBI38 INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION... Walzer, S.
22 S3 p. S424
 artikel
108 PBI69 INSIGHTS INTO FUTURE AUTOIMMUNE PRICING DYNAMICS IN EU5 & THE US, USING LEARNINGS FROM RHEUMATOID ARTHRITIS Smith, L.
22 S3 p. S430
 artikel
109 PBI86 INVESTIGATION ON THE CURRENT STATUS SURROUNDING BIOLOGICS AND THE IMPACT OF BIOSIMILARS USING JAPANESE REAL-WORLD DATA IN FY2017 Tsuchiya, T.
22 S3 p. S433
 artikel
110 PBI5 IS ICER INCREASING INFLUENCE IN THE USA OVER TIME? Stino, M.
22 S3 p. S418
 artikel
111 PBI50 LEVERAGING OUTCOME BASED AND PORTFOLIO AGREEMENTS TO GUARANTEE CLINICAL OUTCOMES: INNOVATIVE PAYMENT MODELS FOR HIGH COST ONE-TIME TREATMENTS Madaan, P.
22 S3 p. S426
 artikel
112 PBI29 LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES Ma, Q.
22 S3 p. S422
 artikel
113 PBI74 MARKET ACCESS LANDSCAPE FOR BIOSIMILARS IN SWEDEN: AN UNTAPPED POTENTIAL? Olsson, K.
22 S3 p. S430-S431
 artikel
114 PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES Wojciechowski, P.
22 S3 p. S429
 artikel
115 PBI57 PAYER AND PHYSICIAN DYNAMICS SURROUNDING BIOSIMILAR ACCESS IN THE EU Gaffney, A.
22 S3 p. S427
 artikel
116 PBI47 PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA Privolnev, Y.
22 S3 p. S425
 artikel
117 PBI77 PAYING FOR CURES: AN ANALYSIS OF INNOVATIVE ACCESS AGREEMENTS FOR LICENSED GENE THERAPIES Hogg, L.
22 S3 p. S431
 artikel
118 PBI81 PERSISTENCE AND HEALTHCARE RESOURCE USE (HCRU) IN PATIENTS INITIATING ETANERCEPT TREATMENT FOR ANKYLOSING SPONDYLITIS (AS) OR PSORIATIC ARTHRITIS (PSA) IN GERMANY: A REAL-WORLD ANALYSIS Baraliakos, X.
22 S3 p. S432
 artikel
119 PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING Colombo, D.
22 S3 p. S434
 artikel
120 PBI44 REAL-WORLD EVIDENCE IN GENE THERAPIES: RECOMMENDATIONS VERSUS REALITY Allen, G.
22 S3 p. S425
 artikel
121 PBI62 REAL-WORLD EVIDENCE ON THERAPEUTIC DRUG MONITORING OF TNF-INHIBITORS IN INFLAMMATORY BOWEL DISEASE Capoulas, M.
22 S3 p. S428
 artikel
122 PBI87 REAL-WORLD GOLIMUMAB EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLARTHRITIS AND A TREATMENT FAILURE TO PREVIOUS TNFΑ INHIBITOR THERAPY Georgiadis, A.
22 S3 p. S433
 artikel
123 PBI58 RESISTANCE TO OR SUPPORT OF BIOSIMILARS' MARKET PENETRATION? A SYSTEMATIC REVIEW OF EUROPEAN STAKEHOLDERS' BEHAVIOURS Braoudaki, E.
22 S3 p. S428
 artikel
124 PBI75 REVIEW OF ECONOMIC EVALUATIONS FOR GENE THERAPIES:ARE WE READY FOR THE FUTURE? ten Ham, R.
22 S3 p. S431
 artikel
125 PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE Daoussis, D.
22 S3 p. S420-S421
 artikel
126 PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE Mestouri, A.
22 S3 p. S421
 artikel
127 PBI56 SUSTAINABLE BIOSIMILAR PROCUREMENT IN EUROPE: A REVIEW OF CURRENT POLICIES AND THEIR POTENTIAL IMPACT Vulto, A.
22 S3 p. S427
 artikel
128 PBI9 SYSTEMATIC LITERATURE REVIEW OF NMAS AND POPULATION ADJUSTED INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PSORIASIS Garcia Llinares, I.
22 S3 p. S419
 artikel
129 PBI1 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS COMPARING NETAKIMAB WITH OTHER BIOLOGIC AGENTS USED TO TREAT ADULT PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN RUSSIA Tolkacheva, D.
22 S3 p. S418
 artikel
130 PBI40 TENDER APPROACHES IN THE OFF-PATENT BIOLOGICAL MEDICINES MARKET: A EUROPEAN COMPARATIVE ANALYSIS Barbier, L.
22 S3 p. S424
 artikel
131 PBI90 THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES Lorenzoni, V.
22 S3 p. S434
 artikel
132 PBI26 THE ECONOMIC REASON FOR THE USE OF VEDOLIZUMAB COMPARED WITH INHIBITORS OF TNF-ALPHA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON THE EXAMPLE OF MOSCOW Kornilova, E.
22 S3 p. S422
 artikel
133 PBI49 THE EXPEDITED REGULATORY PROGRAMS FOR REGENERATIVE MEDICINES IN US, EU AND JAPAN Qiu, T.
22 S3 p. S426
 artikel
134 PBI43 THE IMPACT OF BIOSIMILAR PRICE CONTAGION ON NEW INNOVATION IN INFLAMMATORY DISEASES Teale, C.
22 S3 p. S424-S425
 artikel
135 PBI59 THE REIMBURSEMENT STATUS OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE Hanna, E.
22 S3 p. S428
 artikel
136 PBI13 TNF-ALPHA INHIBITORS IN THE CZECH REPUBLIC: HOW BIOSIMILARS AFFECT OVERALL CONSUMPTION AND COSTS? Chytilová, P.
22 S3 p. S419
 artikel
137 PBI21 TREATMENT COSTS OF MATRIX-ASSOCIATED AUTOLOGOUS CHONDROCYTES IMPLANTATION COMPARED TO MICROFRACTURE — RESULTS OF A MATCHED-PAIR CLAIMS DATA ANALYSIS ON TREATMENT OF CARTILAGE KNEE DEFECTS IN GERMANY Hoburg, A.
22 S3 p. S421
 artikel
138 PBI82 TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCES CONSUMPTION ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AFFECTED BY PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS IN A NORTHERN ITALIAN REGION Perrone, V.
22 S3 p. S432
 artikel
139 PBI60 TRENDS AND UPTAKE OF PREDICTIVE BRCA TESTING Martin, A.
22 S3 p. S428
 artikel
140 PBI36 TRENDS IN THE REGISTRATION OF THERAPEUTIC BIOLOGICS BY THE SAUDI FDA (1989-MAY 2019) Alyousef, A.M.
22 S3 p. S423
 artikel
141 PBI51 TRENDS IN THE THERAPEUTIC BIOLOGICS ATHORIZED BY FDA, EMA AND THE SAUDI FDA IN THE PERIOD 1996-2018 Almutairi, R.
22 S3 p. S426
 artikel
142 PBI8 UNKNOWN Finch, L.
22 S3 p. S419
 artikel
143 PBI45 UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES? Kim, Y.
22 S3 p. S425
 artikel
144 PBI80 VARIATIONS IN TREATMENT PATTERNS OF PSORIASIS PATIENTS CURRENTLY EXPERIENCING 1ST LINE BIOLOGIC THERAPY IN EUROPE Lu, Y.
22 S3 p. S432
 artikel
145 PBI6 WHAT IS THE APPROPRIATE DISCOUNT RATE IN ECONOMIC EVALUATIONS OF GENE THERAPIES (GT)? Velikanova, R.
22 S3 p. S418-S419
 artikel
146 PBI70 WILL CAR-T CELL THERAPIES CHANGE HOW DRUGS ARE PRICED AND REIMBURSED? Macaulay, R.
22 S3 p. S430
 artikel
147 PCN413 A BAYESIAN MIXTURE CURE MODEL USING INFORMATIVE PRIORS Pham, H.A.
22 S3 p. S516
 artikel
148 PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY Hu, J.
22 S3 p. S445
 artikel
149 PCN223 A BUDGET IMPACT ANALYSIS OF A COMMUNITY-BASED SUPPORT CENTRE FOR CANCER PATIENTS AND SURVIVORS Wong Chu, R.
22 S3 p. S479
 artikel
150 PCN446 A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS Jahn, B.
22 S3 p. S522-S523
 artikel
151 PCN181 ACCELERATING EARLY COST-EFFECTIVENESS MODELING IN ONCOLOGY USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A RETROSPECTIVE CASE STUDY OF NIVOLUMAB PRE-TREATED METASTATIC SMALL-CELL LUNG CANCER POPULATION Wu, E.
22 S3 p. S471
 artikel
152 PCN263 ACCESS TO HEALTH SERVICES FOR PEOPLE WITH CANCER IN PERU: TRENDS IN SOCIO-ECONOMIC INEQUALITIES WITHIN THE FRAMEWORK OF A RESULTS-BASED BUDGETING PROGRAM Gutierrez-Aguado, A.
22 S3 p. S486-S487
 artikel
153 PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES Subbotina, E.
22 S3 p. S509
 artikel
154 PCN173 ACCOUNTING FOR TIME-DEPENDENT HEALTH STATE MEMBERSHIP IN BUDGET IMPACT ANALYSIS - CASE STUDY IN ONCOLOGY Litkiewicz, M.
22 S3 p. S469-S470
 artikel
155 PCN462 ACCURACY OF RISK SCORING SYSTEM TO DETERMINE DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS J, H.
22 S3 p. S526
 artikel
156 PCN20 ACCURATE PREDICTIONS OF LIFE YEAR GAINS FOR IMMUNO-ONCOLOGY THERAPIES IN THE LONG TERM? AN ANALYSIS BASED ON PUBLISHED CHECKMATE 057 NIVOLUMAB DATA Porteous, A.
22 S3 p. S438
 artikel
157 PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB Franken, M.G.
22 S3 p. S500
 artikel
158 PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY Cranmer, H.
22 S3 p. S456
 artikel
159 PCN508 A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA von der Heyde, E.
22 S3 p. S536
 artikel
160 PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL Pinheiro, B.
22 S3 p. S450
 artikel
161 PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL Silva Miguel, L.
22 S3 p. S467
 artikel
162 PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE Teitsson, S.
22 S3 p. S448
 artikel
163 PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL Piccolo, F.
22 S3 p. S503
 artikel
164 PCN291 ADEQUATE DATA SOURCES TO FACILITATE INNOVATIVE PRICING SOLUTIONS FOR PHARMACEUTICALS WITH MULTIPLE INDICATIONS IN GERMANY Vogelmann, T.
22 S3 p. S492
 artikel
165 PCN33 ADJUSTED COMPARISON OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS LENALIDOMIDE PLUS DEXAMETHASONE (RD) IN SECOND LINE (2L) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS, USING INDIVIDUAL PATIENT LEVEL DATA (IPD) FROM THE CASTOR AND POLLUX TRIALS Diels, J.
22 S3 p. S441
 artikel
166 PCN320 ADMINISTRATIVE OVERSIGHT SHORTENS WAIT-TIME TO BEGIN RADIOTHERAPY IN THE PUBLIC SYSTEM Beiser, E.
22 S3 p. S498
 artikel
167 PCN405 ADOPTION AND UPTAKE OF LIQUID BIOPSY-BASED NSCLC SOMATIC MUTATION TESTING IN THE EU5 CLINICAL SETTING Carlow, D.
22 S3 p. S515
 artikel
168 PCN368 ADVANCED NMA TECHNIQUES IN NICE STA SUBMISSIONS Garcia, A.
22 S3 p. S508
 artikel
169 PCN61 A FREELY AVAILABLE GENERIC COST-EFFECTIVENESS MODEL IN ONCOLOGY FOR EARLY-STAGE DECISION MAKING Lauppe, R.
22 S3 p. S447
 artikel
170 PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS Kappel, M.
22 S3 p. S468
 artikel
171 PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER Smare, C.
22 S3 p. S481
 artikel
172 PCN10 A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) Fox, C.
22 S3 p. S436-S437
 artikel
173 PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Potluri, R.
22 S3 p. S524
 artikel
174 PCN56 A MEA IS A MEA IS A MEA? ANALYSIS OF THE SEQUENTIAL DECISION MAKING AND THE IMPACT OF DIFFERENT OPTIMIZED MANAGED ENTRY AGREEMENTS AT THE MANUFACTURER &PAYER LEVEL, USING A CASE STUDY OF AN ONCOLOGY DRUG IN THE UK Buyukkaramikli, N.C.
22 S3 p. S446
 artikel
175 PCN361 A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE MAINTENANCE STRATEGIES FOR TREATMENT OF RECENTLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC) WITH BRCA MUTATION UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE Teich, V.
22 S3 p. S506
 artikel
176 PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY Quinn, C.
22 S3 p. S446
 artikel
177 PCN390 ANALYSIS OF INDIRECT TREATMENT COMPARISONS IN ONCOLOGY-RELATED HTA DECISIONS IN GERMANY Hardtstock, F.
22 S3 p. S512
 artikel
178 PCN449 AN ANALYSIS OF EQ-5D ADJUSTING FOR TREATMENT SWITCHING: THE CASE OF PATIENTS WITH EGFR T790M POSITIVE NSCLC TREATED WITH OSIMERTINIB Singh, J.
22 S3 p. S523
 artikel
179 PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS Leeneman, B.
22 S3 p. S534
 artikel
180 PCN155 AN ECONOMIC SYSTEMATIC LITERATURE REVIEW FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC) Robson, R.
22 S3 p. S465
 artikel
181 PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER Smare, C.
22 S3 p. S480
 artikel
182 PCN477 APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY: RESULTS FROM A TOBIT REGRESSION Borchert, K.
22 S3 p. S529
 artikel
183 PCN258 APPLYING BIG DATA ANALYTICS TO DEVELOP PREDICTIVE MODELS FOR ESTIMATING HER2+ BC INCIDENCE AND PREVALENCE IN BRAZIL Rol, R.
22 S3 p. S485-S486
 artikel
184 PCN356 ARE CANCER DRUGS ASSOCIATED WITH A COMPANION DIAGNOSTIC TEST TAKING LONGER TO BE REIMBURSED IN AUSTRALIA? Tran, G.
22 S3 p. S505
 artikel
185 PCN387 ARE NICE APPRAISAL COMMITTEES BEING CONSISTENT IN THEIR IMPLEMENTATION OF THE END OF LIFE CRITERION? Macaulay, R.
22 S3 p. S511-S512
 artikel
186 PCN106 A REVIEW OF DECISION ANALYTIC MODELS TO EVALUATE THE COST-EFFECTIVENESS OF CANCER TREATMENTS: 5-YEARS OF PUBLICATIONS AND SINGLE-TECHNOLOGY APPRAISALS Bullement, A.
22 S3 p. S456-S457
 artikel
187 PCN345 A REVIEW OF DIFFERENCES IN DECISION-MAKING ACROSS NICE HEALTH TECHNOLOGY ASSESSMENTS OF NIVOLUMAB Horscroft, J.
22 S3 p. S503
 artikel
188 PCN371 A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY Zhang, R.
22 S3 p. S508
 artikel
189 PCN282 ASSESSING THE EVOLUTION OF THE PRICING AND ACCESS LANDSCAPE FOR CELL AND GENE THERAPIES IN THE US AND EU3 THROUGH A WEB-BASED PORTAL TO ENGAGE PAYERS Kumar Singh, K.
22 S3 p. S490-S491
 artikel
190 PCN427 ASSESSING THE PERFORMANCE OF PARAMETRIC SURVIVAL MODELS USING REAL WORLD EVIDENCE IN CML, LUNG AND PROSTATE CANCER Paly, V.F.
22 S3 p. S519
 artikel
191 PCN418 ASSESSMENT OF STUDIES EVALUATING INCREMENTAL COSTS, EFFECTIVENESS OR COST-EFFECTIVENESS OF SYSTEMIC THERAPIES IN BREAST CANCER BASED ON CLAIMS DATA: A SYSTEMATIC REVIEW Luyendijk, M.
22 S3 p. S517
 artikel
192 PCN399 ASSESSMENT OF SURROGACY OUTCOMES FOR OVERALL SURVIVAL IN ONCOLOGY BASED ON NICE APPRAISALS AND POST-APPRAISAL EVIDENCE Brown, T.
22 S3 p. S514
 artikel
193 PCN326 ASSESSMENT OF THE ONCOLOGICAL OFFER AMONG ITALIAN REGIONS: A PATIENT-CENTERED ANALYSIS Rova, A.
22 S3 p. S499
 artikel
194 PCN16 ASSESSMENT OF THE QUALITY OF LIFE, PHYSICAL ACTIVITY, DEPRESSION AND ANXIETY OF PATIENTS UNDER ONCOLOGY CARE Horváth, K.
22 S3 p. S438
 artikel
195 PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL Grima, D.
22 S3 p. S458
 artikel
196 PCN511 ASSOCIATED FACTORS AFFECTING RECURRENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA Kang, J.H.
22 S3 p. S537
 artikel
197 PCN528 ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH LUNG CANCER AMONG A U.S. COHORT: A REAL WORLD APPROACH Kashambwa, R.
22 S3 p. S540
 artikel
198 PCN515 A SURVEY OF CLINICAL PRACTICE FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN THE UNITED KINGDOM Robinson, M.
22 S3 p. S538
 artikel
199 PCN488 A SYSTEMATIC LITERATURE REVIEW OF STUDIES REPORTING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH METASTATIC PANCREATIC CANCER BEFORE OR AFTER TREATMENT Yoo, H.K.
22 S3 p. S532
 artikel
200 PCN133 A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF NEWLY DIAGNOSED MULTIPLE MYELOMA Cizova, D.
22 S3 p. S461
 artikel
201 PCN40 A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS Shah, S.N.
22 S3 p. S443
 artikel
202 PCN79 A TARGETED LITERATURE REVIEW (TLR) OF THE EPIDEMIOLOGY AND ECONOMIC BURDEN OF ACUTE MYELOID LEUKEMIA (AML) Panjabi, S.
22 S3 p. S451
 artikel
203 PCN380 A TARGETED REVIEW EVALUATING UNCERTAINTY IN SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS FOR TREATMENTS APPROVED FOR USE SINCE THE INTRODUCTION OF THE 'NEW' CANCER DRUGS FUND Critchlow, S.
22 S3 p. S510
 artikel
204 PCN471 ATTITUDE TOWARDS CERVICAL CANCER SCREENING ATTENDANCE AND NON-ATTENDANCE AMONG ROMANY AND NON-ROMANY WOMEN Pakai, A.
22 S3 p. S528
 artikel
205 PCN458 ATTITUDE TOWARDS PARTICIPATION ON BREAST CANCER SCREENING AND THE ASSESSMENT OF INFLUENCING FACTORS AMONG 45-65 YEARS OLD WOMEN Máté, Z.
22 S3 p. S525
 artikel
206 PCN297 ATTRIBUTE DEVELOPMENT FOR A DISCRETE CHOICE EXPERIMENT (DCE) EXPLORING WILLINGNESS TO PAY (WTP) FOR CURING CANCER Germain, N.
22 S3 p. S493
 artikel
207 PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER Lemeshko, V.
22 S3 p. S488
 artikel
208 PCN534 BARRIERS AND FACILITATORS TO IMPLEMENTING ELECTRONIC PATIENT-REPORTED OUTCOMES (PROS) IN CANCER CLINICAL TRIALS: INTERVIEW RESULTS FROM CLINICAL RESEARCH STAFF AND PATIENTS Fayanju, O.
22 S3 p. S541
 artikel
209 PCN422 BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB Klijn, S.L.
22 S3 p. S518
 artikel
210 PCN409 BAYESIAN NETWORK META-ANALYSIS FOR MIXTURE CURE MODELS Garcia, A.
22 S3 p. S515
 artikel
211 PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF Hall, A.
22 S3 p. S509
 artikel
212 PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE Peduto, I.
22 S3 p. S448-S449
 artikel
213 PCN244 BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Brito Filho, C.
22 S3 p. S483
 artikel
214 PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER Barrón-Barrón, F.
22 S3 p. S459-S460
 artikel
215 PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Kim, H.S.J.
22 S3 p. S462
 artikel
216 PCN175 BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MIDOSTAURIN FOR FLT3-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS). Buehler, A.
22 S3 p. S470
 artikel
217 PCN119 BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL Sakagute, M.
22 S3 p. S459
 artikel
218 PCN174 BUDGET IMPACT OF LEUPROLIDE ACETATE 3-MONTHLY DEPOT FORMULATIONS FOR THE MANAGEMENT OF PATIENTS WITH ADVANCED AND METASTATIC PROSTATE CANCER IN GREECE Solakidi, A.
22 S3 p. S470
 artikel
219 PCN197 BUDGET IMPACT OF LUNG CANCER SCREENING WITH LOW-DOSE COMPUTERIZED TOMOGRAPHY FOR SMOKING GROUPS Tsau, H.S.
22 S3 p. S474
 artikel
220 PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK Møller, A.H.
22 S3 p. S483
 artikel
221 PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS Westerink, L.
22 S3 p. S472
 artikel
222 PCN496 BURDEN OF ACUTE MYELOID LEUKEMIA AMONG NEWLY DIAGNOSED PATIENTS IN SOUTH KOREA: RETROSPECTIVE EMR DATABASE ANALYSIS Jang, J.H.
22 S3 p. S533-S534
 artikel
223 PCN22 BURDEN OF BRAIN METASTASES (BM) IN ALK+ NON-SMALL CELL LUNG CANCER (ALK+ NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR) Pan, X.
22 S3 p. S439
 artikel
224 PCN529 BURDEN OF ILLNESS IN NEW OSTOMATES: AN ANALYSIS BASED ON GERMAN CLAIMS DATA Bassy, N.
22 S3 p. S540-S541
 artikel
225 PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA Lister, J.
22 S3 p. S443
 artikel
226 PCN507 CAN TRANSFERABILITY OF CLINICAL TRIALS POPULATION TO REAL WORLD SETTING BE ASSESSED USING FRENCH NATIONAL HEALTHCARE DATABASE? A CASE STUDY IN ONCOLOGY Medina Diaz, A.
22 S3 p. S536
 artikel
227 PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE HEALTH CARE PERSPECTIVE Tanaka, S.
22 S3 p. S479
 artikel
228 PCN257 CERVICAL CANCER INCIDENCE IN A POPULATION OF 41,202 WOMEN SCREENED BY CONVENTIONAL CYTOLOGY AT A SINGLE PRIVATE LABORATORY OF SOUTHEAST BRAZIL Schultz, M.I.O.
22 S3 p. S485
 artikel
229 PCN300 CERVICAL CANCER PREVENTION IN INDONESIA: AN UPDATED CLINICAL IMPACT, COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS Setiawan, D.
22 S3 p. S494
 artikel
230 PCN323 CHANGE IN TREATMENT PARADIGM OF ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) IN THE ITALIAN REAL PRACTICE Tucci, C.
22 S3 p. S499
 artikel
231 PCN78 CHANGES IN HEALTH STATE COSTS IN HEPATOCELLULAR CARCINOMA (HCC) Muszbek, N.
22 S3 p. S451
 artikel
232 PCN328 CHANGING EPIDEMIOLOGY AND TREATMENT ALGORITHM IN PANCREATIC CANCER IN GERMANY 2017-2018 Kellermann, L.
22 S3 p. S500
 artikel
233 PCN59 CHARACTERISING ERRORS INCURRED BY MODEL SELECTION BASED ON AIC FOR EXTRAPOLATION OF SURVIVAL IN HEALTH TECHNOLOGY ASSESSMENT - A SIMULATION STUDY Young, R.
22 S3 p. S447
 artikel
234 PCN254 CHARACTERISING INDIVIDUALS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING ROUTINE LINKED HEALTH DATASETS: A FEASIBILITY STUDY Arnold, P.
22 S3 p. S485
 artikel
235 PCN461 CHARACTERIZATION OF THE CARE PATHWAYS OF PATIENTS WITH MERKEL CELL CARCINOMA IN FRANCE Croce, I.
22 S3 p. S526
 artikel
236 PCN280 CHARACTERIZING THE CONTINUED RELEVANCE OF IRP IN ITALY: A SIMULATION ANALYSIS OF TOP PRESCRIBED MOLECULES IN ONCOLOGY Trenti, S.
22 S3 p. S490
 artikel
237 PCN53 CHECKPOINT INHIBITOR USE AND THE OCCURRENCE OF INSULIN-DEPENDENT OR DRUG-INDUCED DIABETES: WHAT CAN WE LEARN FROM REAL WORLD DATA? Evans, L.
22 S3 p. S445
 artikel
238 PCN36 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY Mandepudi, A.
22 S3 p. S442
 artikel
239 PCN396 CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS): ARE ONGOING CLINICAL TRIALS DESIGNED TO MEET EVIDENCE NEEDS OF KEY EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES (HTABS)? Agashe, V.
22 S3 p. S513
 artikel
240 PCN350 CLINICAL AND ECONOMIC ASSESSMENT OF THE IMPORTANCE OF SUPPORTIVE THERAPY IN ONCOLOGY Kolbin, A.
22 S3 p. S504
 artikel
241 PCN520 CLINICAL AND ECONOMIC EVALUATIONS OF MULTIPLE MYELOMA PATIENTS Saragoni, S.
22 S3 p. S539
 artikel
242 PCN34 CLINICAL AND HUMANISTIC BURDEN AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW Kwon, C.S.
22 S3 p. S441
 artikel
243 PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE Oriol, A.
22 S3 p. S497-S498
 artikel
244 PCN18 CLINICAL BENEFITS OF REHABILITATION IN PATIENTS WITH ADVANCED CANCER IN KOREA Kang, M.
22 S3 p. S438
 artikel
245 PCN274 CLINICAL FACTORS ASSOCIATED WITH ADHERENCE TO THE SECONDARY SCREENING FOR COLORECTAL CANCER ACCORDING TO AGE IN KOREAN NATIONAL CANCER SCREENING PROGRAM Kang, M.
22 S3 p. S489
 artikel
246 PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY D'Arpino, A.
22 S3 p. S449
 artikel
247 PCN44 COMPARATIVE EFFECTIVENESS OF EARLY VS. LATE USE OF SORAFENIB IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN Chen, H.Y.
22 S3 p. S443-S444
 artikel
248 PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS) Cope, S.
22 S3 p. S440
 artikel
249 PCN32 COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS McGovern, I.
22 S3 p. S441
 artikel
250 PCN351 COMPARATIVE STUDY OF PFS AS PRIMARY ENDPOINT IN EUROPEAN HTA (FRANCE AND GERMANY) Rivière, P.
22 S3 p. S504
 artikel
251 PCN358 COMPARING AND VALIDATING THE OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TREATMENTS APPLIED IN HTA'S BY NOMA AND TLV Johannesen, K.
22 S3 p. S505-S506
 artikel
252 PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS van Oostrum, I.
22 S3 p. S524
 artikel
253 PCN412 COMPARING THE LONG-TERM SURVIVAL METHODOLOGIES IN PHARMACOECONOMIC MODELS OR GLIOBLASTOMA: WHICH BEST REFLECT REAL-WORLD OUTCOMES? Guzauskas, G.
22 S3 p. S516
 artikel
254 PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL Alves, D.
22 S3 p. S463
 artikel
255 PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN Polanco Sánchez, C.
22 S3 p. S458
 artikel
256 PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND Oniangue-Ndza, C.
22 S3 p. S457
 artikel
257 PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY Foix Colonier, A.
22 S3 p. S475
 artikel
258 PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS Kulakova, M.
22 S3 p. S447
 artikel
259 PCN347 COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE Nientker, L.
22 S3 p. S504
 artikel
260 PCN483 CONFIRMING THE PSYCHOMETRIC PERFORMANCE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–MELANOMA (FACT-M) QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA (MCC) Bharmal, M.
22 S3 p. S531
 artikel
261 PCN319 CONTEMPORARY EVIDENCE ON GLOBAL ECONOMIC BURDEN OF FRONTLINE CARE FOR PERIPHERAL T-CELL LYMPHOMA Ashaye, A.O.
22 S3 p. S498
 artikel
262 PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS) Zheng, Y.
22 S3 p. S469
 artikel
263 PCN190 COST–BENEFIT ANALYSIS OF INTERVENTIONS MADE BY PHARMACISTS IN CHEMOTHERAPY PREPARATION OF A REFERRAL HOSPITAL IN IRAN Hajimiri, S.H.
22 S3 p. S473
 artikel
264 PCN98 COST-COMPARISON ANALYSIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) AND TRANSARTERIAL CHEMOEMBOLISATION (TACE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) Muszbek, N.
22 S3 p. S455
 artikel
265 PCN195 COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND GOSERELIN 1-MONTH FORMULATION AS ADJUVANT ENDOCRINE THERAPY IN POST-MASTECTOMY, PREMENOPAUSAL WOMEN WITH EARLY-STAGE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WHO ARE AT MODERATE-TO-HIGH RISK OF RECURRENCE IN CHINA Fan, L.
22 S3 p. S473-S474
 artikel
266 PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE McCrea, C.
22 S3 p. S476
 artikel
267 PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM García San Andrés, B.
22 S3 p. S462
 artikel
268 PCN215 COST COMPARISON OF LENALIDOMIDE BASED TRIPLE COMBINATION THERAPIES FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE KINGDOM OF SAUDI ARABIA Maroun, R.
22 S3 p. S477
 artikel
269 PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA Avxentyev, N.A.
22 S3 p. S511
 artikel
270 PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE Stefani, S.D.
22 S3 p. S478-S479
 artikel
271 PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE Gherardi, A.
22 S3 p. S464-S465
 artikel
272 PCN149 COST-EFFECTIVENESS ANALYSIS OF DABRAFENIB+TRAMETINIB VERSUS WATCHFUL WAITING IN THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED BRAF V600 POSITIVE STAGE III MELANOMA : A FRENCH PERSPECTIVE Cariou, C.
22 S3 p. S464
 artikel
273 PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL Paquete, A.T.
22 S3 p. S448
 artikel
274 PCN145 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB IN ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION IN FRANCE Tetafort, A.
22 S3 p. S463
 artikel
275 PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES Tuffaha, H.
22 S3 p. S454
 artikel
276 PCN234 COST-EFFECTIVENESS ANALYSIS OF HOME-BASED PALLIATIVE CARE FOR END-STAGE CANCER PATIENTS Kubor, P.
22 S3 p. S481
 artikel
277 PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE Diamantogiannis, F.
22 S3 p. S468-S469
 artikel
278 PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE Branchoux, S.
22 S3 p. S477
 artikel
279 PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN Polanco Sánchez, C.
22 S3 p. S466
 artikel
280 PCN156 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA Bellone, M.
22 S3 p. S465-S466
 artikel
281 PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN Taheri, S.
22 S3 p. S472
 artikel
282 PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND Harding, T.
22 S3 p. S473
 artikel
283 PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND Harding, T.
22 S3 p. S473
 artikel
284 PCN230 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA Li, H.
22 S3 p. S480
 artikel
285 PCN101 COST-EFFECTIVENESS ANALYSIS OF TORIPALIMAB VERSUS PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA IN CHINA Lin, Z.
22 S3 p. S455-S456
 artikel
286 PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE Gherardi, A.
22 S3 p. S459
 artikel
287 PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE Tsiatas, M.
22 S3 p. S478
 artikel
288 PCN172 COST-EFFECTIVENESS OF CRC FRENCH SCREENING PROGRAMME FOR AVERAGE RISK INDIVIDUALS Leleu, H.
22 S3 p. S469
 artikel
289 PCN81 COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVE Buehler, A.
22 S3 p. S451
 artikel
290 PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA Yu, Y.
22 S3 p. S467-S468
 artikel
291 PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 TRIAL van Oostrum, I.
22 S3 p. S467
 artikel
292 PCN64 COST-EFFECTIVENESS OF IMATINIB SINCE ITS INTRODUCTION AS FIRST-LINE TREATMENT IN THE NETHERLANDS Wolters, S.
22 S3 p. S447-S448
 artikel
293 PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Aggarwal, H.
22 S3 p. S453-S454
 artikel
294 PCN217 COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK Simon, C.
22 S3 p. S478
 artikel
295 PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM Van Campenhout, H.
22 S3 p. S453
 artikel
296 PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING Di Rienzo, P.
22 S3 p. S451-S452
 artikel
297 PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE Oniangue-Ndza, C.
22 S3 p. S476
 artikel
298 PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE Augusto, M.
22 S3 p. S473
 artikel
299 PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND Oniangue-Ndza, C.
22 S3 p. S462
 artikel
300 PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY Di Rienzo, P.
22 S3 p. S469
 artikel
301 PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067 Baker, T.
22 S3 p. S462-S463
 artikel
302 PCN233 COST EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE VS BENDAMUSTINE ALONE FOR PATIENTS WHO DID NOT RESPOND OR PROGRESSED DURING OR AFTER RITUXIMAB OR A RITUXIMAB CONTAINING REGIMENT IN TURKEY Erdogan-Ciftci, E.
22 S3 p. S481
 artikel
303 PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE Chouaid, C.
22 S3 p. S458
 artikel
304 PCN247 COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB VS TRASTUZUMAB IN NEOADJUVANT SETTING BASED ON THE NEOSPHERE TRIAL IN TURKEY Erdogan-Ciftci, E.
22 S3 p. S483-S484
 artikel
305 PCN231 COST-EFFECTIVENESS OF REGORAFENIB FOR METASTATIC COLORECTAL CANCER IN THE CONTEXT OF THE HEALTHCARE SYSTEM OF KAZAKHSTAN Almadiyeva, A.
22 S3 p. S480-S481
 artikel
306 PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE Buehler, A.
22 S3 p. S466-S467
 artikel
307 PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY Maheshwari, V.
22 S3 p. S470
 artikel
308 PCN85 COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE Kattamis, A.
22 S3 p. S452
 artikel
309 PCN74 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF-MUTATED METASTATIC MELANOMA PATIENTS IN REAL LIFE IN FRANCE Kandel, M.
22 S3 p. S450
 artikel
310 PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE Kandel, M.
22 S3 p. S454-S455
 artikel
311 PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE Stellato, D.
22 S3 p. S453
 artikel
312 PCN204 COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+ BREAST CANCER IN AN INSTITUTION IN PORTUGAL Borges, A.
22 S3 p. S475
 artikel
313 PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY Despiégel, N.
22 S3 p. S458
 artikel
314 PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Brito Filho, C.
22 S3 p. S483
 artikel
315 PCN130 COST OF ILLNESS ANALYSIS: DRUG THERAPY OF PATIENTS WITH MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS IN MOSCOW Fisun, A.
22 S3 p. S461
 artikel
316 PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY Marcellusi, A.
22 S3 p. S452
 artikel
317 PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY Mohamed, H.
22 S3 p. S531-S532
 artikel
318 PCN505 COSTS AND TREATMENT PATHWAYS OF OVARIAN CANCER CARE IN KAZAKHSTAN: RETROSPECTIVE ANALYSIS OF PATIENT-LEVEL ELECTRONIC HEALTH RECORDS Bektur, C.
22 S3 p. S536
 artikel
319 PCN241 COSTS OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE TRANSCEND NHL 001 CLINICAL TRIAL: A MICRO-COSTING STUDY FROM THE SPANISH NATIONAL HEALTH SYSTEM (NHS) PERSPECTIVE Presa, M.
22 S3 p. S482
 artikel
320 PCN129 COST STRUCTURE ANALYSIS: DRUG THERAPY OF PATIENTS WITH STOMACH CANCER IN MOSCOW. ANALYSIS OF PATIENT DETECTION Poliakova, K.
22 S3 p. S460
 artikel
321 PCN83 COST-UTILITY ANALYIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES IN HEPATOCELLULAR CARCINOMA (HCC) Muszbek, N.
22 S3 p. S452
 artikel
322 PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN Taheri, S.
22 S3 p. S477
 artikel
323 PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN. Takumoto, Y.
22 S3 p. S484
 artikel
324 PCN117 COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+ EARLY BREAST CANCER IN SPAIN Colomer, R.
22 S3 p. S458-S459
 artikel
325 PCN199 COST-UTILITY ANALYSIS OF THE BI-, QUADRI-, AND NONA-VALENT HPV-VACCINE: A DECISION ANALYTIC MODEL Hermansen, N.K.
22 S3 p. S474
 artikel
326 PCN159 COST-UTILITY ANALYSIS OF TRIFLURIDINE/TIPIRACIL FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN Takushima, Y.
22 S3 p. S466
 artikel
327 PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS Bellone, M.
22 S3 p. S465
 artikel
328 PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS Verbeek, J.G.E.
22 S3 p. S450
 artikel
329 PCN148 COST-UTILITY OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1+ NSCLC PATIENTS: AN AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE Bellone, M.
22 S3 p. S464
 artikel
330 PCN105 COST-UTILITY OF NIVOLUMAB FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER (R/M SCCHN) IN FRANCE Venkatachalam, M.
22 S3 p. S456
 artikel
331 PCN292 CURRENT AND FUTURE EU5 PAYER LANDSCAPE FOR ONCOLOGY SOMATIC MUTATION PANELS Carlow, D.
22 S3 p. S492
 artikel
332 PCN102 DATA INTELLIGENCE FOR THE EVALUATION OF NEW TREATMENTS FOR BREAST CANCER: QUEST FOR A BETTER METHOD TO ESTIMATE AFFORDABILITY IN SCOTLAND Nagy, R.
22 S3 p. S456
 artikel
333 PCN394 DETERMINANTS OF MANAGED ENTRY AGREEMENTS IN THE CONTEXT OF HTA; EMPIRICAL EVIDENCE FROM ONCOLOGY MEDICINES IN FOUR COUNTRIES. Efthymiadou, O.
22 S3 p. S513
 artikel
334 PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA Tully, S.
22 S3 p. S521
 artikel
335 PCN459 DEVELOPMENT OF A PATIENT-CENTERED CONCEPTUAL MODEL DESCRIBING THE IMPACT OF LIVING WITH HEPATOCELLULAR CARCINOMA Rylands, A.
22 S3 p. S525-S526
 artikel
336 PCN4 DINUTUXIMAB BETA WITH ISOTRETINOIN VERSUS ISOTRETINOIN ALONE IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: IMPACT ON LONG-TERM SURVIVAL Wex, J.
22 S3 p. S435
 artikel
337 PCN97 DIRECT COSTS ASSOCIATED WITH NEUTROPENIA AND FEBRILE NEUTROPENIA AS ADVERSE EVENTS OF CHEMOTHERAPY IN SERBIAN CANCER PATIENTS Lukić, S.
22 S3 p. S455
 artikel
338 PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE Fujii, R.
22 S3 p. S459
 artikel
339 PCN433 DISCRETE TIME RESTRICTED CUBIC SPLINE MODELS FOR NETWORK META-ANALYSIS OF TIME-TO-EVENT OUTCOMES Pletscher, M.
22 S3 p. S520
 artikel
340 PCN469 DISEASE SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS FOR HEMATOLOGIC MALIGNANCIES (HM) Brown Hajdukova, E.
22 S3 p. S528
 artikel
341 PCN362 DO ANTICANCER DRUGS ENTERING THE FRENCH MARKET PROVIDE SIGNIFICANT EVIDENCE OF THEIR CLINICAL EFFICACY? van Hinloopen, O.
22 S3 p. S506-S507
 artikel
342 PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER Privolnev, Y.
22 S3 p. S505
 artikel
343 PCN444 DYNAMIC SURVIVAL MODELS FOR INCORPORATING EXTERNAL EVIDENCE WHEN EXTRAPOLATING OVERALL SURVIVAL: A CASE STUDY. Kearns, B.C.
22 S3 p. S522
 artikel
344 PCN168 ECONOMIC BURDEN OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CLAIMS-BASED ANALYSIS Griffin, J.
22 S3 p. S468
 artikel
345 PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS Ball, G.
22 S3 p. S521
 artikel
346 PCN166 ECONOMIC EVALUATION OF ANTICANCER DRUGS: A SYSTEMATIC REVIEW ON COST-EFFECTIVENESS STUDIES BASED ON HEALTHCARE SYSTEM CLAIMS DATABASES Bouee Benhamiche, E.
22 S3 p. S468
 artikel
347 PCN184 ECONOMIC EVALUATION OF CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADVANCED MELANOMA IN THE IRISH HEALTHCARE SETTING Gorry, C.
22 S3 p. S471-S472
 artikel
348 PCN73 ECONOMIC EVALUATION OF TARGETED TREATMENTS FOR BRAFV600 POSITIVE MELANOMA IN THE IRISH HEALTHCARE SETTING Gorry, C.
22 S3 p. S449
 artikel
349 PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN Sheikhi, S.
22 S3 p. S477
 artikel
350 PCN144 ECONOMIC EVALUATIONS OF CANCER INTERVENTIONS IN SPAIN: LITERATURE REVIEW Pomares, E.
22 S3 p. S463
 artikel
351 PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING Thavorn, K.
22 S3 p. S461-S462
 artikel
352 PCN279 EFFECT OF THE CHANGE IN COST-EFFECTIVENESS THRESHOLD ON THE NEWLY LISTED ANTICANCER DRUG PRICES IN THE NATIONAL HEALTH INSURANCE OF SOUTH KOREA Choi, S.E.
22 S3 p. S490
 artikel
353 PCN54 EFFICACY AND SAFETY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED, ADVANCED STAGE MYCOSIS FUNGOIDES AND SÉZARY SYNDROME PATIENTS: A POST-HOC ANALYSIS OF THE MAVORIC STUDY Leoni, M.
22 S3 p. S445-S446
 artikel
354 PCN431 EFFICACY PREDICTION IN PHASE I ONCOLOGY CLINICAL TRIALS USING DEEP LEARNING Aouchiche, B.
22 S3 p. S519-S520
 artikel
355 PCN209 END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE: A HOSPITAL-BASED RETROSPECTIVE STUDY Kourlaba, G.
22 S3 p. S476
 artikel
356 PCN147 ENTRECTINIB IN NTRK TUMOR AGNOSTIC INDICATION COMPARED TO DIFFERENT STANDARD OF CARE IN VARIOUS TUMORS TYPES: A COST-EFFECTIVENESS ANALYSIS IN ITALIAN PATIENTS Bellone, M.
22 S3 p. S464
 artikel
357 PCN273 EPIDEMIOLOGY AND UNMET NEEDS OF BLADDER CANCER IN ITALY De Nunzio, C.
22 S3 p. S488-S489
 artikel
358 PCN75 EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER - A MULTIPLE COUNTRY ANALYSIS Włodek, B.
22 S3 p. S450
 artikel
359 PCN180 EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ + CARBOPLATIN + ETOPOSIDE VS. CARBOPLATIN + ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) Orfanos, P.
22 S3 p. S471
 artikel
360 PCN65 ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN Suarez Rodriguez, J.
22 S3 p. S448
 artikel
361 PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB Reese, E.
22 S3 p. S501
 artikel
362 PCN268 ESTIMATING THE BURDEN OF MALIGNANT HAEMATOPOIETIC CANCERS IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS Sharma, A.
22 S3 p. S487-S488
 artikel
363 PCN264 ESTIMATING THE BURDEN OF SALIVARY GLAND CANCER IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS Pandey, S.
22 S3 p. S487
 artikel
364 PCN261 ESTIMATING THE NUMBER OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE ACROSS EUROPE Agh, T.
22 S3 p. S486
 artikel
365 PCN262 ESTIMATION OF THE NUMBER OF PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN PORTUGAL Cardoso, M.
22 S3 p. S486
 artikel
366 PCN255 ESTIMATION OF THE POTENTIAL IMPACT OF THE FRENCH CRC SCREENING PROGRAM BASED ON REAL-WORLD PARTICIPATION RATES Leleu, H.
22 S3 p. S485
 artikel
367 PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB Kiiskinen, U.
22 S3 p. S539-S540
 artikel
368 PCN463 EUROQOL-5D ASSESSED HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS VS. GENERAL POPULATION IN BULGARIA Encheva-Malinova, M.
22 S3 p. S526
 artikel
369 PCN70 EVALUATING AN ONLINE CALCULATOR FOR ANALYZING DRUG COSTS OF THERAPY OF METASTATIC BREAST CANCER IN RUSSIAN FEDERATION: A NATIONAL PERSPECTIVE Krysanov, I.
22 S3 p. S449
 artikel
370 PCN6 EVALUATING THE QUALITY AND RISK OF BIAS IN OVERALL SURVIVAL OUTCOMES FROM NON-RANDOMISED CAR T-CELL THERAPY PIVOTAL TRIALS Carey, N.
22 S3 p. S436
 artikel
371 PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS McLean, C.
22 S3 p. S520
 artikel
372 PCN8 EXAMINATION OF FACTORS INFLUENCING THE OCCURRENCE OF THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS (MPN) BASED ON HUNGARIAN NATIONAL REGISTRY DATA Dombi, P.
22 S3 p. S436
 artikel
373 PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER Rivera, F.
22 S3 p. S528
 artikel
374 PCN278 EXPLORING PRE AND POST AGENZIA ITALIANA DEL FARMACO (AIFA) REIMBURSED ACCESS TO IMMUNOTHERAPY FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) Wellam, H.
22 S3 p. S490
 artikel
375 PCN516 EXPLORING THE CURRENT STATUS OF NEUROENDOCRINE TUMOURS: A POPULATION-BASED ANALYSIS OF EPIDEMIOLOGY, MANAGEMENT AND USE OF RESOURCES Darba, J.
22 S3 p. S538
 artikel
376 PCN340 FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA Italia, N.
22 S3 p. S502
 artikel
377 PCN48 FEASIBILITY OF EXTRACTING SURVIVAL DATA FROM PUBLISHED LITERATURE USING THE GUYOT ALGORITHM Pritchard, C.
22 S3 p. S444
 artikel
378 PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA Cozzone, D.
22 S3 p. S540
 artikel
379 PCN450 FITTING A MIXTURE MODEL OF CANCER EXCESS MORTALITY RATES WITH A TRANSFORMATION STEP, TO CANCER RELATIVE SURVIVAL DATA. Martin, C.
22 S3 p. S523
 artikel
380 PCN58 FOUR-STATE MARKOV MODEL FOR IMMUNO-ONCOLOGIC THERAPIES Young, R.
22 S3 p. S446-S447
 artikel
381 PCN198 FRACTIONAL POLYNOMIAL MODELS FOR NETWORK META-ANALYSIS OF SURVIVAL DATA IN ECONOMIC EVALUATIONS: A CASE-STUDY ON THE COST-EFFECTIVENESS OF FULVESTRANT IN PREVIOUSLY-TREATED POSTMENOPAUSAL, OESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER Burton, H.
22 S3 p. S474
 artikel
382 PCN310 "FREE” VS "CONTROLLED” PRICING SYSTEM: A EUROPEAN ASSESSMENT OF THE DISPARITIES IN ACCESS TO ONCOLOGY DRUGS Gas, N.
22 S3 p. S496
 artikel
383 PCN305 FUNDING TRENDS FOR IN-HOSPITAL DRUGS: GERMAN NUB ANALYSIS Sanchez Vazquez, B.
22 S3 p. S495
 artikel
384 PCN386 GERMAN BENEFIT ASSESSMENT IN THE FIELD OF ONCOLOGY: FACTORS INFLUENCING THE BENEFIT RATING IN ADDITION TO COMPLYING WITH THE APPROPRIATE COMPARATOR Ulrich, S.
22 S3 p. S511
 artikel
385 PCN250 GLOBAL DISTRIBUTION AND TREND IN TREATMENT NEEDS OF FEMALE BREAST CANCER Chen, Y.C.
22 S3 p. S484
 artikel
386 PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL Alves, D.
22 S3 p. S483
 artikel
387 PCN13 HANNA – REAL-WORLD EVIDENCE FROM A GERMAN, PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH NIVOLUMAB IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) von der Heyde, E.
22 S3 p. S437
 artikel
388 PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION Redig, J.
22 S3 p. S475
 artikel
389 PCN510 HEALTHCARE RESOURCE UTILISATION (HCRU) ASSOCIATED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLISATION (TACE) TREATMENT IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS IN EUROPE Bailey, T.
22 S3 p. S537
 artikel
390 PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE Goldschmidt, H.
22 S3 p. S479
 artikel
391 PCN86 HEALTHCARE RESOURCE UTILIZATION FOR CETUXIMAB + CHEMOTHERAPY ADMINISTERED EVERY OTHER WEEK VS ONCE WEEKLY FOR TREATMENT OF METASTATIC COLORECTAL CANCER: REAL-WORLD OUTCOMES FROM A US CLAIMS DATABASE STUDY Pescott, C.
22 S3 p. S452-S453
 artikel
392 PCN100 HEALTH-ECONOMIC EVALUATION OF LUNG CANCER DRUGS: DO S AND DON TS IN FRANCE Sivignon, M.
22 S3 p. S455
 artikel
393 PCN466 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CLINICAL PRACTICE FOR IMMUNE-CHECKPOINT INHIBITORS (ICI)-TREATED PATIENTS: WHAT ARE PATIENTS' EXPERIENCES AND EXPECTATIONS? RESULTS FROM AN ONLINE PATIENT COMMUNITY RESEARCH Wilczynski, O.
22 S3 p. S527
 artikel
394 PCN464 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF CANCER PATIENTS TREATED WITH IMMUNOTHERAPY: USE OF SOCIAL MEDIA IN FRENCH LANGUAGE TO EXPLORE RELEVANCE OF CONCEPTS COVERED BY CANCER GENERIC HRQOL MEASURES Faviez, C.
22 S3 p. S526-S527
 artikel
395 PCN478 HEALTH-RELATED QUALITY OF LIFE OF CANCER PATIENTS IN JAPAN: A POPULATION-BASED NATIONAL HEALTH AND WELLNESS SURVEY STUDY Tsukamoto, K.
22 S3 p. S529-S530
 artikel
396 PCN93 HEALTH RESOURCE UTILIZATION IN ADVANCED OVARIAN AND ENDOMETRIAL CANCER IN A UNITED STATES INSURANCE CLAIMS DATABASE Galaznik, A.
22 S3 p. S454
 artikel
397 PCN286 HEALTH TECHNOLOGY ASSESSMENT DECISIONS OVER THE LAST DECADE IN THE UNITED KINGDOM AND THE NETHERLANDS - A FOCUS ON NON-SMALL-CELL LUNG CANCER Westerink, L.
22 S3 p. S491
 artikel
398 PCN271 HODGKIN LYMPHOMA IN EUROPEAN COUNTRIES: A TARGETED LITERATURE REVIEW Musku, K.
22 S3 p. S488
 artikel
399 PCN411 HOW ARE SINGLE-ARM TRIALS PERCEIVED IN HEATH TECHNOLOGY ASSESSMENTS FOR CHRONIC LEUKAEMIA ACROSS THE EU5, AUSTRALIA AND CANADA? Barwood, C.
22 S3 p. S516
 artikel
400 PCN88 HOW ARE WE ASSESSING THE VALUE FOR MONEY OF CANCER BIOMARKERS IN ECONOMIC EVALUATIONS? Seo, M.K.
22 S3 p. S453
 artikel
401 PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY? Russell, J.
22 S3 p. S514-S515
 artikel
402 PCN341 HOW INFLUENTIAL IS BUDGET IMPACT IN DETERMINING PRICING FOR ONCOLOGY PRODUCTS?: A REGRESSION ANALYSIS Xia, A.
22 S3 p. S502
 artikel
403 PCN288 HOW IS METASTATIC MELANOMA TREATED IN THE PUBLIC HEALTH SYSTEM IN BRAZIL?: A CALL FOR CHANGE Marques dos Santos, A.
22 S3 p. S491-S492
 artikel
404 PCN379 HTA ASSESSMENTS OF METASTATIC UROTHELIAL CARCINOMA TREATMENT IN EU COUNTRIES Benisheva, T.
22 S3 p. S510
 artikel
405 PCN337 HTA DECISIONS IN FRANCE AND GERMANY: LESSONS FROM MELANOMA Benassi, F.
22 S3 p. S501-S502
 artikel
406 PCN331 HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA Panjabi, S.
22 S3 p. S500
 artikel
407 PCN308 IDENTIFICATION OF VARIABLES THAT MAY INFLUENCE THE RECOMMENDATION INCLUDED IN THE THERAPEUTIC POSITIONING REPORT OF NEW ONCOLOGY PRODUCTS IN SPAIN Celik, H.
22 S3 p. S496
 artikel
408 PCN403 IDENTIFYING KEY CRITERIA FOR HEALTH TECHNOLOGY ASSESSMENT FOR ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL: A MCDA APPROACH Amaral, L.M.
22 S3 p. S514
 artikel
409 PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS Kumar Singh, K.
22 S3 p. S490
 artikel
410 PCN321 IMAGING SURVEILLANCE OF PATIENTS WITH OVARIAN CANCER AFTER SUCCEEDING EARLY TREATMENT: A CROSS-SECTIONAL ANALYSIS FROM REAL-WORLD DATA Cho, J.Y.
22 S3 p. S498
 artikel
411 PCN38 IMPACT OF CERVICAL CANCER SCREENING TIME ON SURGICAL OUTCOMES Schultz, L.
22 S3 p. S442
 artikel
412 PCN25 IMPACT OF GEMTUZUMAB OZOGAMICIN ON THE IRISH HEALTHCARE SYSTEM Gallagher, J.
22 S3 p. S439-S440
 artikel
413 PCN531 IMPACT OF GENETIC POLYMORPHISMS OF XRCC1 AND XRCC3 GENES AND THEIR ROLE IN PROSTATE CANCER RISKS IN BANGLADESHI POPULATION Khan, R.A.
22 S3 p. S541
 artikel
414 PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURDEN OF CLL IN CANADA Lachaine, J.
22 S3 p. S481-S482
 artikel
415 PCN363 IMPACT OF OUTCOMES ON IQWIGS OVERALL BENEFIT RATING During, S.
22 S3 p. S507
 artikel
416 PCN125 IMPACT OF PALLIATIVE CARE CONSULT SERVICES ON THE COST OF CARE IN HUNGARY Zemplényi, A.
22 S3 p. S460
 artikel
417 PCN530 IMPACT OF SUBSEQUENT TREATMENT CHOICE AND SURROGACY ASSUMPTIONS IN HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER TREATMENT PATHWAY MODELLING Ralph, L.
22 S3 p. S541
 artikel
418 PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING Tai, T.A.
22 S3 p. S464
 artikel
419 PCN290 IMPLEMENTATION OF COMBINATION THERAPY PRICING RULES IN ONCOLOGY: LESSONS FROM MULTIPLE MYELOMA Rowbottom, R.
22 S3 p. S492
 artikel
420 PCN298 IMPROVED DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS Ledovskikh, Y.
22 S3 p. S494
 artikel
421 PCN435 IMPROVED ESTIMATES OF EXTRAPOLATED MEAN SURVIVAL TIMES USING FINITE MIXTURE MODELS: REDUCING UNCERTAINTY IN COST EFFECTIVENESS ANALYSIS Cislo, P.
22 S3 p. S520
 artikel
422 PCN370 IMPROVING PATIENT ACCESS TO INNOVATIVE MEDICATIONS WHILE PROTECTING PUBLIC BUDGETS SUSTAINABILITY: AN ALTERNATIVE GO TO MARKET AND PRICING FRAMEWORK TO ENABLE VALUE CO-CREATION BETWEEN PHARMAS AND PAYERS Lor, S.
22 S3 p. S508
 artikel
423 PCN307 IMPROVING PATIENT ACCESS TO PD-(L)1 THERAPIES IN CHINA: POLICY IMPLICATIONS FROM PREVIOUS NRDL NEGOTIATIONS Jin, J.
22 S3 p. S495-S496
 artikel
424 PCN448 IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS Bennison, C.
22 S3 p. S523
 artikel
425 PCN523 INCIDENCE AND COST OF NON-CERVICAL HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED CANCER IN KOREA Choi, I.
22 S3 p. S539
 artikel
426 PCN269 INCIDENCE OF FECAL AND URINARY INCONTINENCE IN PATIENTS WITH A DIAGNOSIS OF RECTAL CARCINOMA Schiffmann, L.
22 S3 p. S488
 artikel
427 PCN414 INCLUSION OF SUBSEQUENT TREATMENTS WITH CURATIVE INTENT IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PARTITIONED SURVIVAL MODELS Muszbek, N.
22 S3 p. S516
 artikel
428 PCN339 INCORPORATING COMPANION DIAGNOSTICS (CDX) IN COST-EFFECTIVENESS MODELS (CEMS) SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). A REVIEW El Alili, H.
22 S3 p. S502
 artikel
429 PCN397 INCORPORATING RISK SCORES IN CRC SCREENING MODELS: A EXAMPLE FROM THE INCA-PHE CRC MODEL Leleu, H.
22 S3 p. S513
 artikel
430 PCN154 INCORPORATING THE VALUE HEALTHY INDIVIDUALS PLACE ON GENEROUS INSURANCE COVERAGE OF SEVERE DISEASES: A STATED PREFERENCE SURVEY OF ADULT COHORTS WITH AND AT-RISK FOR LUNG CANCER Shafrin, J.
22 S3 p. S465
 artikel
431 PCN443 INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB Chamard, P.
22 S3 p. S522
 artikel
432 PCN49 INDIRECT COMPARISON OF HRQOL DATA FOR PATIENTS WITH TREATMENT-REFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE & TIPIRACIL (PRECONNECT TRIAL) COMPARED WITH BSC & REGORAFENIB (CORRECT TRIAL) Moreno, S.
22 S3 p. S444-S445
 artikel
433 PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS Kommoju, U.J.
22 S3 p. S445
 artikel
434 PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL) Oluwole, O.
22 S3 p. S522
 artikel
435 PCN417 INFLUENCE 2.0: A TIME-DEPENDENT MODEL TO PREDICT LOCOREGIONAL RECURRENCE AND SECOND PRIMARIES IN EARLY BREAST CANCER PATIENTS Voelkel, V.
22 S3 p. S517
 artikel
436 PCN277 INTER-REGIONAL INEQUALITY IN ITALIAN HEALTHCARE DELIVERY AFFECTS CHOICE OF SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE BREAST CANCER Wellam, H.
22 S3 p. S489
 artikel
437 PCN27 INTRAPATIENT COMPARISONS IN SINGLE ARM TRIALS FOR TUMOR AGNOSTIC INDICATIONS WITH APPLICATION TO ENTRECTINIB Bennett, I.
22 S3 p. S440
 artikel
438 PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS Boehmer, C.
22 S3 p. S503
 artikel
439 PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA? Betts, K.A.
22 S3 p. S482
 artikel
440 PCN303 ITALIAN NATIONAL HEALTH SERVICE REIMBURSEMENT POLICY FOR ONCOLOGY DRUGS AFTER CONDITIONAL MARKET AUTHORIZATION GRANTED BY THE EUROPEAN MEDICINE AGENCY: A RETROSPECTIVE ANALYSIS Lazzaro, C.
22 S3 p. S495
 artikel
441 PCN338 KEY DRIVERS OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR RELAPSED-REFRACTORY MULTIPLE MYELOMA TREATMENTS; A COUNTRY COMPARISON. Horsburgh, S.
22 S3 p. S502
 artikel
442 PCN381 KEY FACTORS FOR THE CONSIDERATION OF QUALITY OF LIFE DATA IN AMNOG BENEFIT ASSESSMENTS Billig, S.
22 S3 p. S510-S511
 artikel
443 PCN327 KEY INTERVALS IN THE PATIENT JOURNEY OF MEN WITH PROSTATE CANCER: EVIDENCE FROM GREECE Naoum, V.
22 S3 p. S499-S500
 artikel
444 PCN276 KNOWLEDGE AND BELIEFS ABOUT CANCER - RESULTS OF QUALITATIVE INTERVIEWS WITH THE GENERAL POPULATION IN FRANCE Germain, N.
22 S3 p. S489
 artikel
445 PCN202 LIQUID BIOPSY FOR EGFR+ PATIENTS IN ADVANCED NSCLC: THE IMPACT OF DIFFERENT STRATEGIES Gancitano, G.
22 S3 p. S475
 artikel
446 PCN490 MAKING OUTCOME-BASED PAYMENT A REALITY IN THE NATIONAL HEALTH SERVICE FOR ENGLAND Cole, A.
22 S3 p. S532
 artikel
447 PCN90 MANAGEMENT AND COST OF FEBRILE NEUTROPENIA (FN) IN THE ONCOLOGY PATIENT van Gogh, E.
22 S3 p. S453
 artikel
448 PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS Cocklin, S.L.
22 S3 p. S529
 artikel
449 PCN14 MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS Chu, P.
22 S3 p. S437
 artikel
450 PCN389 MATURE VERSUS REGISTRATION STUDIES OF IMMUNO-ONCOLOGY AGENTS: DOES VALUE IMPROVE WITH TIME? Ben-Aharon, O.
22 S3 p. S512
 artikel
451 PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA? Raad, A.
22 S3 p. S503
 artikel
452 PCN423 MEASURING FATIGUE SYMPTOMS AND IMPACTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EVALUATING DIMENSIONALITY OF THE FACIT-FATIGUE Hintzen, C.L.
22 S3 p. S518
 artikel
453 PCN239 MEDICAL COST OF RITUXIMAB-CONTAINING THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA IN JAPAN: R-B IS LESS EXPENSIVE THAN R-CHOP Shoji, A.
22 S3 p. S482
 artikel
454 PCN481 METHODOLOGICAL ASPECTS OF HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER IN CLINICAL TRIALS: A SYSTEMATIC REVIEW. Ou, Z.
22 S3 p. S530
 artikel
455 PCN372 METHODOLOGIES FOR ADJUSTMENT OF THE TRIAL OVERALL SURVIVAL FOR TREATMENT SWITCHING: A REVIEW OF NICE SUBMISSIONS Gurskyte, L.
22 S3 p. S508-S509
 artikel
456 PCN28 METHOD TO ESTIMATE IMPACT OF PROGNOSTIC FACTORS ON SURVIVAL OUTCOMES USING MAXIMUM LIKELIHOOD ESTIMATION Snedecor, S.J.
22 S3 p. S440
 artikel
457 PCN299 MINIMUM VOLUME STANDARDS IN FRENCH HOSPITALS FOR BREAST CANCER AND OVARIAN CANCER - INEQUALITIES IN ACCESS TO HOSPITAL CARE Huguet, M.
22 S3 p. S494
 artikel
458 PCN453 MODELING THE IMPACT OF NEXT GENERATION SEQUENCING BASED COMPREHENSIVE GENOMIC PROFILING PANEL ON TREATMENT PRACTICES IN ADVANCED OR METASTATIC CANCER Quon, P.
22 S3 p. S524
 artikel
459 PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS Kroep, S.
22 S3 p. S523-S524
 artikel
460 PCN178 MODELLING THE BUDGET IMPACT OF INTRODUCING 3D MAMMOGRAPHY FOR BREAST CANCER SCREENING IN GERMANY Schubert, T.
22 S3 p. S471
 artikel
461 PCN312 MULTIPLE MYELOMA IN A SWISS POPULATION: REAL-WORLD DRUG REGIMENS AND COSTS OF TREATMENT (2012 TO 2017) Eichler, K.
22 S3 p. S496
 artikel
462 PCN506 MUTATION TESTING AND TREATMENT OF THE MOST COMMON ONCOLOGY DISEASES IN GERMANY: ANALYSIS OF AN ONCOLOGY EMR DATABASE Wilke, T.
22 S3 p. S536
 artikel
463 PCN110 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF MALIGNANT MELANOMA OF SKIN IN HUNGARY: COST OF ILLNESS PILOT STUDY BASED ON REAL WORLD DATA Pörneczy, E.
22 S3 p. S457
 artikel
464 PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE Lim, S.W.
22 S3 p. S475-S476
 artikel
465 PCN55 NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2- ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY LeReun, C.
22 S3 p. S446
 artikel
466 PCN424 NETWORK META-ANALYSIS FOR IMMUNE ONCOLOGY TRIALS USING SPLINES Ouwens, D.M.
22 S3 p. S518
 artikel
467 PCN416 NETWORK META-ANALYSIS FOR SURROGATE ENDPOINT EVALUATION IN ADVANCED COLORECTAL CANCER: A BAYESIAN APPROACH Bujkiewicz, S.
22 S3 p. S516-S517
 artikel
468 PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE) Goring, S.
22 S3 p. S521
 artikel
469 PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE? Sroczynski, G.
22 S3 p. S443
 artikel
470 PCN302 NEW DRG-BASED REIMBURSEMENT OF RADIATION THERAPY AT RUSSIAN HOSPITALS Ledovskikh, Y.
22 S3 p. S494-S495
 artikel
471 PCN420 NEW METHODOLOGIES IN PARAMETRIC NETWORK META-ANALYSIS: ACCOUNTING FOR POPULATION AGE DIFFERENCES BETWEEN TRIALS van Beekhuizen, S.
22 S3 p. S517
 artikel
472 PCN441 NEW METHODOLOGY IN NETWORK META-ANALYSIS USING MIXTURE CURE MODELS van Oostrum, I.
22 S3 p. S522
 artikel
473 PCN447 NEW METHODOLOGY IN PARAMETRIC NETWORK META-ANALYSIS: NON-MIXTURE CURE MODELS van Beekhuizen, S.
22 S3 p. S523
 artikel
474 PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN Presa, M.
22 S3 p. S457
 artikel
475 PCN46 NOVEL APPROACHES TO ADDRESS RESISTANCE TO ANTI PD-1/PD-L1 THERAPY IN NSCLC Sehgal, M.
22 S3 p. S444
 artikel
476 PCN127 NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE TRIPLETS DRD AND KRD FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA IN THE BRAZILIAN PRIVATE SYSTEM Decimoni, T.
22 S3 p. S460
 artikel
477 PCN272 OBINUTUZUMAB TREATMENT ON 1ST LINE HIGH AND INTERMEDIATE RISK FOLLICULAR LYMPHOMA. SHORT-TERM REDUCTION OF RELAPSED OR REFRACTORY DIRECT MEDICAL COSTS IN ARGENTINA AND CHILE. Penayo, N.
22 S3 p. S488
 artikel
478 PCN518 ONCOLOGY REAL WORLD DATA (RWD): ENABLING LEARNING HEALTH SYSTEMS Arondekar, B.
22 S3 p. S538-S539
 artikel
479 PCN400 ONCOLOGY-RELATED HTA DECISIONS IN GERMANY, FRANCE, SPAIN AND THE UK: ASSESSMENT OF SIMILARITIES AND DIFFERENCES Hardtstock, F.
22 S3 p. S514
 artikel
480 PCN311 OPTIMAL BREAST CANCER SCREENING POLICY STRATIFYING BY BREAST DENSITY Shen, Y.
22 S3 p. S496
 artikel
481 PCN177 ORGANIZATIONAL AND ECONOMIC IMPACT OF NEXT GENERATION SEQUENCING AND HOTSPOT APPROACH Baggi, A.
22 S3 p. S470
 artikel
482 PCN51 OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Cardoso, P.
22 S3 p. S445
 artikel
483 PCN296 OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND Doolub, N.
22 S3 p. S493
 artikel
484 PCN153 OVERVIEW OF ECONOMIC EVALUATIONS OF ONCOLOGY PRODUCTS WITH A FOCUS ON THE KEY CHALLENGES ACROSS, UNITED KINGDOM, FRANCE AND CANADA Ferrer, J.
22 S3 p. S465
 artikel
485 PCN336 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WOULD ONE SUBMISSION FIT ALL? Gibson, S.
22 S3 p. S501
 artikel
486 PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY Oguzhan Ergın, G.
22 S3 p. S494
 artikel
487 PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS Torvinen, S.
22 S3 p. S466
 artikel
488 PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE Minga, E.
22 S3 p. S487
 artikel
489 PCN472 PATIENT REPORTED HEALTH STATE UTILITIES IN CUTANEOUS T-CELL LYMPHOMA (CTCL) - AN ANALYSIS OF EQ-5D AND SKINDEX-29 DATA COLLECTED FROM THE ALCANZA TRIAL Podkonjak, T.
22 S3 p. S528
 artikel
490 PCN482 PATIENT-REPORTED OUTCOME MEASURES IN BREAST CANCER: A SYSTEMATIC REVIEW OF EORTC QLQ-C30, FACT-B, AND EORTC QLQ-BR23 DEVELOPMENT AND VALIDATION Ou, Z.
22 S3 p. S530
 artikel
491 PCN485 PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3 MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY Cella, D.
22 S3 p. S531
 artikel
492 PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS Quek, R.G.W.
22 S3 p. S532
 artikel
493 PCN479 PATIENT-REPORTED SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE: A SYSTEMATIC LITERATURE REVIEW Csanádi, M.
22 S3 p. S530
 artikel
494 PCN385 PAY-FOR-PERFORMANCE IN ONCOLOGY: A SUCCESSFUL STORY FROM BULGARIA Borissov, B.
22 S3 p. S511
 artikel
495 PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA) McGovern, I.
22 S3 p. S444
 artikel
496 PCN475 PERCEPTIONS AND EXPERIENCES OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: A UK CASE STUDY Penaloza Ramos, C.
22 S3 p. S529
 artikel
497 PCN493 PERCEPTIONS OF AND PARTICIPATION IN REAL-WORLD EVIDENCE RESEARCH AMONG US COMMUNITY ONCOLOGISTS Klink, A.
22 S3 p. S533
 artikel
498 PCN185 PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS: A 4-YEAR EXPERIENCE Monteiro, I.
22 S3 p. S472
 artikel
499 PCN378 PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER Kolbin, A.
22 S3 p. S510
 artikel
500 PCN335 PHARMACOECONOMIC PERSPECTIVES ON THE USE OF INOTUZUMAB OZOGAMICIN IN THE TREATMENT OF RELAPSED OR REFRACTORY FORMS OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Kolbin, A.
22 S3 p. S501
 artikel
501 PCN526 PHYSICIAN ACCEPTANCE OF REAL-WORLD EVIDENCE IN DRUG APPROVAL AND LABELING Kish, J.K.
22 S3 p. S540
 artikel
502 PCN314 POPULATION BASED STUDY OF BASELINE BONE DENSITY SCREENING IN PROSTATE CANCER PATIENTS TREATED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY Hu, J.
22 S3 p. S497
 artikel
503 PCN293 POST-PROGRESSION ENDPOINTS IN ONCOLOGY TRIALS: CURRENT CLINICAL AND REIMBURSEMENT PERSPECTIVES Abraham, A.
22 S3 p. S492-S493
 artikel
504 PCN240 POTENTIAL BUDGET IMPACT OF ADJUVANT TREATMENTS FOR STAGE III MELANOMA IN IRELAND Gorry, C.
22 S3 p. S482
 artikel
505 PCN494 POTENTIAL USE OF ARTIFICIAL INTELLIGENCE TO ANALYZE DATA EXTRACTED FROM ELECTRONIC HEALTH RECORDS FOR DECISION ANALYTIC MODELS Kovács, S.
22 S3 p. S533
 artikel
506 PCN357 PREDICTOR OF A POSITIVE RECOMMENDATION IN NICE ONCOLOGY APPRAISALS Laskier, V.
22 S3 p. S505
 artikel
507 PCN333 PREFERENCE ELICITATION FOR CANCER TREATMENT IN EUROPE: A SYSTEMATIC LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS Krinke, K.S.
22 S3 p. S501
 artikel
508 PCN473 PREFERENCES FOR CHEMOTHERAPY SIDE EFFECTS IN SAUDI BREAST CANCER PATIENTS: A DISCRETE-CHOICE EXPERIMENT Alaqeel, S.
22 S3 p. S528-S529
 artikel
509 PCN324 PRELIMINARY EVIDENCE SUGGESTS THAT WE MOVE TOWARDS THE USE OF LIQUID BIOPSIES TO PREDICT RESPONSE TO TKI INHIBITORS: A SYSTEMATIC REVIEW van Delft, F.
22 S3 p. S499
 artikel
510 PCN284 PRESCRIBING TRENDS ACROSS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER IN IRELAND Gorry, C.
22 S3 p. S491
 artikel
511 PCN267 PREVALENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: A COMPARATIVE ANALYSIS OF CLAIMS DATA AND REGISTRY DATA IN GERMANY Hardtstock, F.
22 S3 p. S487
 artikel
512 PCN1 PROGNOSTIC FACTORS ASSOCIATED WITH REAL WORLD PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA TREATED WITH COBIMETINIB COMBINED WITH VEMUIRAFENIB, USING SURVIVAL DECISION TREE TECHNIQUE Meyer, N.
22 S3 p. S435
 artikel
513 PCN512 PROGRESSION, OVERALL SURVIVAL, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY: A SWEDISH REGISTER-BASED STUDY Svensson, J.
22 S3 p. S537
 artikel
514 PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS Shaikh, P.
22 S3 p. S437-S438
 artikel
515 PCN455 QUALITY OF LIFE OF PATIENTS LIVING WITH METASTATIC COLORECTAL CANCER (MCRC): FINAL RESULTS FROM A EUROPEAN PATIENT SURVEY Benedict, Á.
22 S3 p. S524-S525
 artikel
516 PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL Polanco Sánchez, C.
22 S3 p. S440
 artikel
517 PCN289 READINESS OF HEALTH SYSTEMS FOR THE INTRODUCTION OF TUMOUR-AGNOSTIC TREATMENT Vora, D.
22 S3 p. S492
 artikel
518 PCN325 REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS: DIVERGENCE FROM EVIDENCE-BASED MEDICINE Feinberg, B.A.
22 S3 p. S499
 artikel
519 PCN2 REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE: PRELIMINARY RESULTS FROM A REGISTRY Kourlaba, G.
22 S3 p. S435
 artikel
520 PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE Kourlaba, G.
22 S3 p. S435-S436
 artikel
521 PCN313 REAL-WORLD DATA ON THE USE OF ANTINEOPLASTIC PHARMACOTHERAPY REGIMENS AMONG PATIENTS WITH SKIN MELANOMA IN RUSSIA Ledovskikh, Y.
22 S3 p. S496-S497
 artikel
522 PCN47 REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA Barros, C.
22 S3 p. S444
 artikel
523 PCN509 REAL-WORLD EVIDENCE ON PATIENTS WITH RELAPSED/REFRACTORY FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA IN ITALY La Malfa, P.
22 S3 p. S536-S537
 artikel
524 PCN498 REAL-WORLD EVIDENCE ON THE UTILISATION OF ABIRATERONE AND ENZALUTAMIDE IN IRELAND Trela-Larsen, L.
22 S3 p. S534
 artikel
525 PCN519 REAL WORLD EVIDENCE (RWE): ANALYSIS OF THE PROGNOSIS OF PATIENTS WITH METASTATIC COLON CANCER UNDER BIOLOGIC TREATMENT IN THE SOCIAL SECURITY SECTOR OF ARGENTINA Ruiz, J.I.
22 S3 p. S539
 artikel
526 PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY Danesi, V.
22 S3 p. S451
 artikel
527 PCN200 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM MALIGNANT MELANOMA, A FINNISH REGISTRY STUDY Oddershede, L.
22 S3 p. S474
 artikel
528 PCN456 REAL WORLD HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR FIRST LINE RECURRENT/ METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) PATIENTS Singh, P.
22 S3 p. S525
 artikel
529 PCN489 REAL WORLD MULTI-COUNTRY RETROSPECTIVE STUDY OF TREATMENT TRAVEL TIME AND WORK PRODUCTIVITY BURDEN AMONG HER2- NEGATIVE ADVANCED BREAST CANCER PATIENTS WITH A BRCA1/2 MUTATION Niyazov, A.
22 S3 p. S532
 artikel
530 PCN504 REAL-WORLD PROGRESSION-FREE AND OVERALL SURVIVAL OF METASTATIC BREAST CANCER PATIENTS: ANALYSIS OF A NEW GERMAN EMR DATASET Wilke, T.
22 S3 p. S535
 artikel
531 PCN495 REAL WORLD STUDIES IN ONCO-HEMATOLOGY: WHICH PARAMETER SHOULD BE USED TO MEASURE THE EFFICACY OF TREATMENTS? Chalubert, H.
22 S3 p. S533
 artikel
532 PCN499 REAL WORLD TREATMENT AND SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: AN ANALYSIS USING JAPANESE CLAIMS DATA Ghiani, M.
22 S3 p. S534
 artikel
533 PCN514 REAL WORLD TREATMENT PATHWAYS OF DIFFUSE LARGE B-CELL LYMPHOMA IN GERMAN CLAIMS DATA Veltmar, A.
22 S3 p. S538
 artikel
534 PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL Melo, A.C.
22 S3 p. S534-S535
 artikel
535 PCN126 REAL-WORLD TREATMENT SEQUENCING OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): WHAT ARE THE HEALTH ECONOMIC IMPLICATIONS? Pereira-Salgado, A.
22 S3 p. S460
 artikel
536 PCN373 RECENT COST PER QALY TRENDS OF NON-HAEMATOLOGICAL CANCERS ASSESSMENT AT NICE Mondal, S.
22 S3 p. S509
 artikel
537 PCN353 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON NON-SMALL CELL LUNG CANCER: RESULTS, RATIONALE, AND TRENDS Kanaskar, A.
22 S3 p. S504-S505
 artikel
538 PCN354 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS Campbell, D.
22 S3 p. S505
 artikel
539 PCN437 RECONSTRUCTION OF INDIVIDUAL PATIENT DATA FROM PUBLISHED SURVIVAL CURVES: CASE OF PRALATREXATE FOR PERIPHERAL T-CELL LYMPHOMAS Cho, H.
22 S3 p. S521
 artikel
540 PCN242 REDEFINING VALUE IN ONCOLOGY: APPLICATION OF MIXTURE CURE MODELS FOR ECONOMIC ANALYSES OF NOVEL THERAPIES FOR SMALL CELL LUNG CANCER (SCLC) Roth, J.
22 S3 p. S482-S483
 artikel
541 PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES Corredoira, L.
22 S3 p. S531
 artikel
542 PCN304 REIMBURSEMENT AND PAYER MANAGEMENT OF IMMUNE CHECKPOINT INHIBITORS IN KEY EUROPEAN MARKETS Vasiliou, C.
22 S3 p. S495
 artikel
543 PCN364 REIMBURSEMENT OF CAR-T CELL THERAPY IN THE UK, A STEP TOWARDS MORE PERSONALISED CANCER TREATMENT Shaw, C.
22 S3 p. S507
 artikel
544 PCN19 RELATIONSHIP OF STATIN OR ANTI PLATELET AGENTS AND HEPATOCELLULAR CARCINOMA IN TREATMENT NAIVE PATIENTS WITH CHB Kim, H.J.
22 S3 p. S438
 artikel
545 PCN480 RELEVANCE OF SELECTED PATIENT-REPORTED OUTCOME (PRO) MEASURES IN EPSTEIN-BARR VIRUS ASSOCIATED (EBV+) POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) PATIENTS Watson, C.
22 S3 p. S530
 artikel
546 PCN112 RESEARCH TREND OF THE PHARMACOECONOMIC STUDIES OF SMALL-MOLECULE PROTEIN KINASE INHIBITORS IN CHINA Gu, S.
22 S3 p. S457-S458
 artikel
547 PCN210 RESOURCE UTILIZATION AND COST FOR WOMEN WITH ADVANCED HR+/HER2- BREAST CANCER IN COLOMBIAN HEALTH CARE SETTINGS Franco, S.
22 S3 p. S476
 artikel
548 PCN436 RESPONSIVENESS OF THE EQ-5D-5L AND EORTC QLU-C10D IN CANCER PATIENTS Luo, N.
22 S3 p. S520-S521
 artikel
549 PCN256 RESULTS FROM THE CALIBRATION OF A MICROSIMULATION COLON CANCER SCREENING FRENCH MODEL Leleu, H.
22 S3 p. S485
 artikel
550 PCN502 RETROSPECTIVE GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] STUDY ON INITIAL TREATMENT OF BLADDER CARCINOMA (BCA) BY TRANSURETHRAL BLADDER RESECTION (TURB) - A COMPARATIVE ANALYSIS OF COSTS AND UROLOGICAL FOLLOW-UP THERAPIES USING STANDARD WHITE LIGHT- (WL-) VS. BLUE LIGHT- (BL-)TURB Maas, M.
22 S3 p. S535
 artikel
551 PCN513 RETROSPECTIVE STUDY DESCRIBING THE DEMOGRAPHIC CHARACTERISTICS, INCIDENCE, TREATMENT, COMORBIDITIES, MORTALITY, AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH MYELOFIBROSIS AND POLYCYTHEMIA VERA IN SWEDEN Lundqvist, I.
22 S3 p. S537
 artikel
552 PCN393 REVIEW AND VALIDATION OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL EXTRAPOLATION IN TECHNOLOGY APPRAISAL (TA) 366 BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) Papadakis-Sali, A.
22 S3 p. S512-S513
 artikel
553 PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS Yurkova, Y.
22 S3 p. S486
 artikel
554 PCN252 RISK OF LUNG CANCER AMONG SMOKING WOMEN TREATED WITH RADIOTHERAPY FOR PRIMARY BREAST CANCER: FRENCH PROSPECTIVE COHORT STUDY Dohollou, N.
22 S3 p. S484
 artikel
555 PCN391 RISK-SHARING AGREEMENTS FOR ONCOLOGY DRUGS IN SWEDEN – THE NEW STANDARD FOR ACCESS? Olsson, K.
22 S3 p. S512
 artikel
556 PCN3 RITUXIMAB-BASED REGIMEN AS FRONTLINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD NATIONWIDE COHORT STUDY Ko, B.S.
22 S3 p. S435
 artikel
557 PCN30 ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Sen, P.
22 S3 p. S440-S441
 artikel
558 PCN428 SCALABLE PREDICTION OF CANCER PATIENT CLINICAL EVENTS IN REAL WORLD CLINICAL SETTINGS Ransom, J.
22 S3 p. S519
 artikel
559 PCN167 SELF-REPORTED OUT-OF-POCKET EXPENSES, INCOME LOSS, AND INFORMAL CARE INCURRED BY CANCER PATIENTS IN SAUDI ARABIA Alaqeel, S.
22 S3 p. S468
 artikel
560 PCN163 SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA Rochau, U.
22 S3 p. S467
 artikel
561 PCN259 SKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: EMERGING TRENDS FROM THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM Pundole, X.
22 S3 p. S486
 artikel
562 PCN134 SOCIO-ECONOMIC COSTS OF BREAST CANCER: AN ITALIAN ANALYSIS Gazzillo, S.
22 S3 p. S461
 artikel
563 PCN407 SOMATOSTATIN ANALOGUES IN IMAGING OF BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS Singh, B.
22 S3 p. S515
 artikel
564 PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Cakar, E.
22 S3 p. S517-S518
 artikel
565 PCN367 STOOL DNA TESTING FOR EARLY DETECTION OF COLORECTAL CANCER Stürzlinger, H.
22 S3 p. S507-S508
 artikel
566 PCN360 SURROGATE ENDPOINT VALIDATION STUDIES SUBMITTED TO THE GERMAN HEALTH TECHNOLOGY ASSESSMENT AUTHORITY, THE FEDERAL JOINT COMMITTEE (G-BA). CASE STUDIES IN ONCOLOGY Gudelj, M.
22 S3 p. S506
 artikel
567 PCN35 SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME Hamashima, C.
22 S3 p. S442
 artikel
568 PCN460 SYSTEMATIC LITERATURE REVIEW FOR UTILITY DATA IN ACUTE MYELOID LEUKEMIA Bartlett, C.
22 S3 p. S526
 artikel
569 PCN484 SYSTEMATIC REVIEW OF A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN PATIENTS WITH MULTIPLE MYELOMA: EORTC QLQ-MY20 INSTRUMENT DEVELOPMENT AND VALIDATION Ou, Z.
22 S3 p. S531
 artikel
570 PCN104 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES OF CANCER IMMUNOTHERAPY MEDICINES Voh, Ž.
22 S3 p. S456
 artikel
571 PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS Frederickson, A.
22 S3 p. S461
 artikel
572 PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS Frederickson, A.
22 S3 p. S527-S528
 artikel
573 PCN265 TARGETED REVIEW OF ADVERSE EVENTS ASSOCIATED WITH TREATMENTS FOR STAGE 3 AND 4 MELANOMA Llewellyn, S.
22 S3 p. S487
 artikel
574 PCN295 THE BEHAVIOUR OF THE CANCER DRUGS FUND (CDF) OVER TIME; THE IMPACT OF INNOVATIVE THERAPIES AND IMPLICATIONS FOR MANAGED ENTRY AGREEMENTS MacDonald, D.
22 S3 p. S493
 artikel
575 PCN37 THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER Chen, C.H.
22 S3 p. S442
 artikel
576 PCN402 THE CLINICAL AND ECONOMIC CONSEQUENCES OF DELAYS IN REIMBURSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA Leinwand, B.
22 S3 p. S514
 artikel
577 PCN94 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT DRUGS FOR FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA Krysanova, V.
22 S3 p. S454
 artikel
578 PCN69 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TARGET DRUGS FOR SECOND-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA Krysanova, V.
22 S3 p. S449
 artikel
579 PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA Zhao, M.M.
22 S3 p. S455
 artikel
580 PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK Ntais, D.
22 S3 p. S480
 artikel
581 PCN188 THE COST-EFFECTIVENESS OF PARENTERAL NUTRITION IN ONCOLOGY Hancock, E.
22 S3 p. S472
 artikel
582 PCN434 THE EFFECT MODIFICATION PROBLEM: USING STRATIFIED MATCHING ADJUSTED INDIRECT COMPARISON TO EVADE MISLEADING INTERPRETATIONS OF THE TREATMENT EFFECT Rasouliyan, L.
22 S3 p. S520
 artikel
583 PCN521 THE FINANCIAL IMPACT OF AFATINIB REIMBURSEMENT FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER: THE REAL-WORLD EVIDENCE IN TAIWAN Huang, S.H.
22 S3 p. S539
 artikel
584 PCN429 THE GENERATION OF SYNTHETIC CLINICAL TRIAL DATA Mosquera, L.
22 S3 p. S519
 artikel
585 PCN275 THE GLOBAL EPIDEMIOLOGY OF PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW Abogunrin, S.
22 S3 p. S489
 artikel
586 PCN467 THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW Cizova, D.
22 S3 p. S527
 artikel
587 PCN294 THE IMPACT OF VALUE-BASED CARE ON ONCOLOGY SPECIALTY PHYSICIANS Lord, K.
22 S3 p. S493
 artikel
588 PCN398 THE IMPORTANCE OF DIFFERENT ENDPOINTS IN ONCOLOGY-RELATED HEALTH TECHNOLOGY ASSESSMENTS: RESULTS OF A REVIEW OF DECISIONS IN GERMANY Hardtstock, F.
22 S3 p. S513
 artikel
589 PCN251 THE INCIDENCE OF SOFT TISSUE SARCOMA OVER THE NEXT TWO DECADES (2018-2040) Kumar, S.
22 S3 p. S484
 artikel
590 PCN306 THE MODEL OF OUTCOMES-BASED RISK SHARING AGREEMENTS APPLIED TO TARGETED DRUGS IN ONCOLOGY Rihova, B.
22 S3 p. S495
 artikel
591 PCN476 THE PATIENT JOURNEY WITH METASTATIC PROSTATE CANCER: A PILOT QUALITATIVE STUDY FROM GREECE Karampli, E.
22 S3 p. S529
 artikel
592 PCN285 THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION Odnoletkova, I.
22 S3 p. S491
 artikel
593 PCN287 THE ROLE OF EFFICACY AND EFFECTIVENESS ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS IN DETERMINING TENDERING RANKS FOR ONCOLOGY DRUGS IN DENMARK & NORWAY Stephens, T.J.
22 S3 p. S491
 artikel
594 PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS Dorme, L.
22 S3 p. S525
 artikel
595 PCN216 THE SOCIETAL IMPACT OF LENALIDOMIDE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY Hofmann, S.
22 S3 p. S478
 artikel
596 PCN342 THE UPTAKE AND IMPACT OF THE EQ-5D-5L VALUE SET IN NICE TECHNOLOGY APPRAISALS WITHIN ONCOLOGY Walder, L.
22 S3 p. S502-S503
 artikel
597 PCN419 THE USE OF INDIVIDUAL PATIENT-LEVEL DATA (IPD) TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS) IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) Kroi, F.
22 S3 p. S517
 artikel
598 PCN7 THE VALUE OF OBINUTUZUMAB FOR UNTREATED ADVANCED FOLLICULAR LYMPHOMA: AN ASSESSMENT BASED ON MULTICRITERIA DECISION ANALYSIS (MCDA) Friggi, E.
22 S3 p. S436
 artikel
599 PCN365 TITLE: REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN ONCOLOGY Thokagevistk, K.
22 S3 p. S507
 artikel
600 PCN382 TRASTUZUMAB IN THE TREATMENT OF HER2-POSITIVE EARLY ANDLOCALLY ADVANCED BREAST CANCER: THE FIRST HTA REPORT OF INEAS-TUNISIA Jameleddine, M.
22 S3 p. S511
 artikel
601 PCN224 TREATMENT BENEFIT DISCONTINUATION: COMPARISON OF A PARTITIONED SURVIVAL ANALYSIS AND A SEMI-MARKOV MULTI-STATE MODEL APPROACH USING AN ONCOLOGY CASE STUDY Cranmer, H.
22 S3 p. S479
 artikel
602 PCN21 TREATMENT COMPARISONS IN PATIENTS WITH UNRESECTABLE HEPTOCELLULAR CARCINOMA (HCC) WHO ARE INELIGIBLE FOR TRANSARTERIAL CHEMOEMBOLISATION (TACE) Evans, R.
22 S3 p. S438-S439
 artikel
603 PCN366 TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS Henry, A.
22 S3 p. S507
 artikel
604 PCN322 TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY Danese, M.
22 S3 p. S498-S499
 artikel
605 PCN492 TREATMENT PATTERN OF HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR-2 NEGATIVE ADVANCED BREAST CANCER PATIENTS: ANALYSIS OF REAL-WORLD NATIONAL CLAIMS DATA Park, J.A.
22 S3 p. S533
 artikel
606 PCN31 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN SECOND-LINE (2L) ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN ASIAN VERSUS WESTERN COUNTRIES Jaffe, D.
22 S3 p. S441
 artikel
607 PCN9 TREATMENT PATTERNS AND SURVIVAL IN UNRESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CANCER IN THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) MEDICARE LINKED DATA Danese, M.
22 S3 p. S436
 artikel
608 PCN329 TREATMENT PATTERNS IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PATIENTS IN SPAIN. Polanco Sánchez, C.
22 S3 p. S500
 artikel
609 PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND Spyridonidis, A.
22 S3 p. S442-S443
 artikel
610 PCN316 TREATMENT PATTERNS OF ADVANCED SOFT-TISSUE SARCOMA IN ARGENTINA Novick, D.
22 S3 p. S497
 artikel
611 PCN179 TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS Bungey, G.
22 S3 p. S471
 artikel
612 PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN COLOMBIA van Beurden-Tan, C.
22 S3 p. S480
 artikel
613 PCN24 TYROSINE KINASE INHIBITORS: REAL WORLD EVIDENCE ABOUT HEALTH OUTCOMES IN A MIDDLE INCOME COUNTRY Gonzalez, J.
22 S3 p. S439
 artikel
614 PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Cakar, E.
22 S3 p. S439
 artikel
615 PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND Yi, Y.
22 S3 p. S462
 artikel
616 PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM) Gezin, A.
22 S3 p. S515-S516
 artikel
617 PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS Bapat, B.
22 S3 p. S535
 artikel
618 PCN315 USE OF NOVEL HORMONAL AGENTS IN THE MONTH BEFORE DYING IN MEN DYING OF PROSTATE CANCER Hu, J.
22 S3 p. S497
 artikel
619 PCN527 US HEALTHCARE DATABASES FOR HEALTH ECONOMIC MODELING IN PRECISION MEDICINE: AN ONCOLOGY-BASED COMPARATIVE LANDSCAPE ASSESSMENT Herrera-Restrepo, O.
22 S3 p. S540
 artikel
620 PCN430 USING BAYESIAN METHODOLOGIES TO INFORM IMMATURE SURVIVAL EXTRAPOLATIONS BASED ON RWD AND EXPERT ELICITATION IN NON-SMALL CELL LUNG CANCER (NSCLC) El Alili, H.
22 S3 p. S519
 artikel
621 PCN12 USING CLINICAL DATA STANDARDS TO FACILITATE COMPARISONS OF ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES IN REAL WORLD CLINICAL CARE AND POOLED CLINICAL TRIAL POPULATIONS Galaznik, A.
22 S3 p. S437
 artikel
622 PCN392 UTILISATION OF REAL-WORLD EVIDENCE IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SUBMISSIONS OF THE TOP 20 ONCOLOGY DRUGS Papadakis-Sali, A.
22 S3 p. S512
 artikel
623 PCN120 UTILIZATION AND EXPENDITURE OF COLORECTAL CANCER DRUGS IN THE MEDICAID PROGRAM FROM 1996 TO 2017 Alharthi, S.
22 S3 p. S459
 artikel
624 PCN317 VALIDATION OF A STANDARD SET OF PATIENT-CENTERED OUTCOMES FOR LUNG CANCER IN SPAIN Escudero, V.
22 S3 p. S497
 artikel
625 PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA Kurt, M.
22 S3 p. S463-S464
 artikel
626 PCN359 VALUE ASSESSMENT OF HTA DECISIONS FOR PD-1/PD-L1 INHIBITORS IN ONCOLOGY: A NICE PERSPECTIVE Bamrara, A.
22 S3 p. S506
 artikel
627 PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS? Franken, M.G.
22 S3 p. S535
 artikel
628 PCN349 VALUE OF INFORMATION ANALYSIS GUIDING THE REIMBURSEMENT DECISION OF OLAPARIB FOR METASTATIC BREAST CANCER Tuffaha, H.
22 S3 p. S504
 artikel
629 PCN60 VALUE OF NEOADJUVANT IO THERAPIES WITH OR WITHOUT ADJUVANT CANCER THERAPIES: A MODEL FRAMEWORK Benedict, Á.
22 S3 p. S447
 artikel
630 PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS Schneider, P.
22 S3 p. S538
 artikel
631 PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY Richardson, D.
22 S3 p. S527
 artikel
632 PCN369 WHAT IS THE REGULATORY AND HTA LANDSCAPE OF NON-SMALL CELL LUNG CANCER DRUGS ACROSS THE EU5 COUNTRIES? Inumerable, R.V.F.
22 S3 p. S508
 artikel
633 PCN219 WHAT IS WORTH KNOWING AT EARLY DEVELOPMENT? VALUE OF INFORMATION ANALYSIS USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A CASE STUDY Wu, E.
22 S3 p. S478
 artikel
634 PCN426 WHEN CROSS-OVER ISN'T CROSS OVER. STRATEGIES FOR HANDLING EFFECTIVE SUBSEQUENT THERAPIES IN ECONOMIC ANALYSIS OF ONCOLOGY TRIALS Chapman, R.
22 S3 p. S518
 artikel
635 PCN375 WHEN EARLY MODELS MAY BE TOO EARLY - PREDICTING SURVIVAL FROM INTERIM ANALYSES Ayers, D.
22 S3 p. S509
 artikel
636 PCN377 WHERE DO WE GO WITH WHOLE GENOME SEQUENCING IN ONCOLOGY? USING SCENARIO DRAFTING TO EXPLORE FUTURE DEVELOPMENTS van de Ven, M.
22 S3 p. S509-S510
 artikel
637 PCN532 WOMEN'S PREFERENCES ON BENEFITS, RISKS, AND SIDE EFFECTS OF MAINTENANCE PARP INHIBITOR THERAPY IN OVARIAN CANCER Havrilesky, L.J.
22 S3 p. S541
 artikel
638 PCV12 ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH HISTORY OF MYOCARDIAL INFARCTION IN FRANCE USING SNDS DATABASE Schiele, F.
22 S3 p. S543
 artikel
639 PCV137 ADHERENCE TO ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS OF A MULTI-COUNTRY STUDY Mueller, S.
22 S3 p. S567
 artikel
640 PCV156 A MULTILEVEL ACCESS EVIDENCE FRAMEWORK FOR INNOVATIVE TECHNOLOGIES SPECIFIC TO HAEMATOLOGICAL MALIGNANCIES Harrison, K.
22 S3 p. S571
 artikel
641 PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018) Németh, N.
22 S3 p. S558
 artikel
642 PCV95 ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES Mitkova, Z.
22 S3 p. S559
 artikel
643 PCV27 AN ECONOMIC ANALYSIS OF ENDOVASCULAR ARTERIOVENOUS FISTULAS IN DIALYSIS PATIENTS: A U.S. PAYER AND PROVIDER PERSPECTIVE Barclay, B.
22 S3 p. S546
 artikel
644 PCV154 A NOVEL PREDICTION FOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE Lee, J.
22 S3 p. S571
 artikel
645 PCV106 ANTIHYPERTENSIVE AGENT UTILIZATION AMONG PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE UNITED STATES LaVallee, C.
22 S3 p. S561
 artikel
646 PCV144 ANTITHROMBOTIC PRESCRIBING IN A SOUTH AFRICAN PRIVATE HEALTHCARE SETTING, WITH THE FOCUS ON RIVAROXABAN Truter, I.
22 S3 p. S568-S569
 artikel
647 PCV132 APPLYING EUROQOL-5D IN MIDDLE EASTERN PATIENTS WITH CARDIOVASCULAR DISEASES (CVD); A SAUDI PERSPECTIVE Almuaither, N.
22 S3 p. S566
 artikel
648 PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS Proudfoot, C.
22 S3 p. S557
 artikel
649 PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS Walsh, K.
22 S3 p. S560-S561
 artikel
650 PCV145 ASSOCIATION BETWEEN NICORANDIL AND GASTROINTESTINAL ULCERS: A POPULATION-BASED STUDY Kim, S.
22 S3 p. S569
 artikel
651 PCV86 ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY WITH CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN POST-MI PATIENTS IN GERMANY. Sidelnikov, E.
22 S3 p. S557
 artikel
652 PCV120 A STATISTICAL COMPARISON OF LOGISTIC REGRESSION VERSUS MACHINE LEARNING TREE-BASED CLASSIFICATION METHODS IN PREDICTING CORONARY HEART DISEASE USING REAL-WORLD PATIENT-LEVEL DATA Smolen, H.
22 S3 p. S563-S564
 artikel
653 PCV104 A SYSTEMATIC REVIEW OF ORGANISATIONAL AND SERVICE SPECIFICATION RECOMMENDATIONS FOR CENTRES PROVIDING PERCUTANEOUS CORONARY INTERVENTIONS O'Brien, K.K.
22 S3 p. S560
 artikel
654 PCV82 ATHEROSCLEROSIS: BURDEN OF DISEASE IN PORTUGAL Alarcão, J.
22 S3 p. S556
 artikel
655 PCV141 ATHEROSCLEROSIS: REAL-WORLD INSIGHTS FROM A PORTUGUESE PRIMARY CARE DATABASE Ascenção, R.
22 S3 p. S568
 artikel
656 PCV45 ATHEROSCLEROSIS: THE COST OF ILLNESS IN PORTUGAL Alarcão, J.
22 S3 p. S548-S549
 artikel
657 PCV97 BARRIERS THAT AFFECT ADHERENCE AND PERSISTENCE TO NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILATION (AF) IN TURKEY: A DELPHI STUDY. Aras, D.
22 S3 p. S559
 artikel
658 PCV43 BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER FOR THE TREATMENT OF LARGE VESSEL STROKES: A U.S. PAYER PERSPECTIVE Ehm, A.
22 S3 p. S548
 artikel
659 PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN Lizano-Díez, I.
22 S3 p. S547
 artikel
660 PCV46 BUDGET IMPACT OF A DUAL-LAYER STENT RETRIEVER (DLSR) IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) FROM HOSPITAL'S PERSPECTIVE IN FRANCE AND SWEDEN Ehm, A.
22 S3 p. S549
 artikel
661 PCV67 BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE Kalogeropoulou, M.
22 S3 p. S553
 artikel
662 PCV60 BURDEN OF CARDIOVASCULAR DISEASE AND POTENTIAL IMPACT OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN SWITZERLAND Pemberton-Ross, P.
22 S3 p. S552
 artikel
663 PCV11 BURDEN OF HOSPITALISATIONS/READMISSIONS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION – A LITERATURE REVIEW Gogna, S.
22 S3 p. S543
 artikel
664 PCV6 BURDEN OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW Gogna, S.
22 S3 p. S542
 artikel
665 PCV78 BURDEN OR ATRIAL FIBRILLATION AND BUDGET IMPACT OF DABIGATRAN IN ALGERIA Soualmi, R.
22 S3 p. S555
 artikel
666 PCV91 CHANGES IN THE MORTALITY RELATED TO ISCHAEMIC HEART DISEASE IN PEOPLE ABOVE 65 YEARS BETWEEN 1990-2015 IN WHO EUROPEAN REGION Németh, N.
22 S3 p. S558
 artikel
667 PCV28 CHARACTERIZATION OF COSTS AND PATIENTS WITH INCIDENT HEART FAILURE (HF) INCURRING THE HIGHEST HEALTHCARE COSTS FROM SECONDARY CARE: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY IN SWEDEN Boman, K.
22 S3 p. S546
 artikel
668 PCV146 CHARACTERIZATION OF PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY) Teixeira Rodrigues, A.
22 S3 p. S569
 artikel
669 PCV5 3C-HF PROGNOSTIC SCORE TO PREDICT WORSENING CARDIAC FUNCTION AMONG CONGESTIVE HEART FAILURE PATIENTS IN UNITED STATES AND EUROPE Rusli, E.
22 S3 p. S542
 artikel
670 PCV23 CLINICAL AND ECONOMIC IMPACT OF NON-VKA ANTICOAGULANTS INCREASED USE IN THE TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION IN SPAIN BASED ON REAL-LIFE DATA Escobar Cervantes, C.
22 S3 p. S545
 artikel
671 PCV72 CLINICAL AND ECONOMIC IMPLICATIONS OF USING NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION USING AVAILABLE EVIDENCE FROM REAL-WORLD EXPERIENCE Lorenzoni, V.
22 S3 p. S554
 artikel
672 PCV14 COMPARATIVE EFFECTIVENESS AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED COHORT STUDY Perreault, S.
22 S3 p. S543-S544
 artikel
673 PCV19 COMPARATIVE RISK OF HEART FAILURE HOSPITALIZATIONS ASSOCIATED WITH DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS: A POPULATION-BASED COHORT STUDY Shao, S.C.
22 S3 p. S544-S545
 artikel
674 PCV76 COMTEMPORARY HEART FAILURE TREATMENT PATTERN AND COST IN CHINESE PATIENTS POPULATIONS Zhang, M.
22 S3 p. S555
 artikel
675 PCV75 COST ANALYSIS OF COMPLICATIONS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN TURKEY Kockaya, G.
22 S3 p. S555
 artikel
676 PCV32 COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA Mitkova, Z.
22 S3 p. S547
 artikel
677 PCV44 COST ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ROSUVASTATIN AND EZETIMIBE IN THE GREEK SETTING Stafylas, P.
22 S3 p. S548
 artikel
678 PCV42 COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS Walter, E.
22 S3 p. S548
 artikel
679 PCV49 COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS de Andrés-Nogales, F.
22 S3 p. S549-S550
 artikel
680 PCV69 COST EFFECTIVENESS ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN STEMI PATIENTS FROM NATIONAL HEART INSTITUTE PERSPECTIVE IN EGYPT Abourawash, A.
22 S3 p. S554
 artikel
681 PCV109 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS FOR THE MINIMALLY INVASIVE SUTURELESS AORTIC VALVE REPLACEMENT IN PATIENTS WITH AORTIC STENOSIS IN POLAND Lipka, I.
22 S3 p. S561-S562
 artikel
682 PCV29 COST-EFFECTIVENESS OF CORONARY AND PERIPHERAL ARTERY DISEASE TREATMENTS Soini, E.
22 S3 p. S546
 artikel
683 PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN Lindgren, P.
22 S3 p. S548
 artikel
684 PCV30 COST-EFFECTIVENESS OF NOACS IN PATIENTS WITH ATRIAL FIBRILLATION: USING REAL-WORLD DATA FOR EXTERNAL VALIDATION de Jong, L.
22 S3 p. S546
 artikel
685 PCV94 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN LITHUANIA Kockaya, G.
22 S3 p. S558-S559
 artikel
686 PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY Oguzhan Ergın, G.
22 S3 p. S552
 artikel
687 PCV48 COST EFFECTIVENESS OF RIVAROXABAN IN CORONARY ARTERY DISEASE AND/OR PERIPHERAL ARTERY DISEASE FOR 5 DIFFEREN PATIENT SUB-GROUPS IN TURKEY Kockaya, G.
22 S3 p. S549
 artikel
688 PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK Cowie, M.R.
22 S3 p. S550
 artikel
689 PCV157 COST-EFFECTIVENESS OF RIVAROXABAN 2.5 MG BID WITH ASA VERSUS ASA MONOTHERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN SLOVAKIA Psota, M.
22 S3 p. S571
 artikel
690 PCV74 COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE Kalogeropoulou, M.
22 S3 p. S555
 artikel
691 PCV73 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING Hori, M.
22 S3 p. S554-S555
 artikel
692 PCV155 COST-EFFECTIVENESS OF SECOND-LINE CEFTAZIDIME-AVIBACTAM IN PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIA INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA IN TAIWAN Chen, Y.C.
22 S3 p. S571
 artikel
693 PCV110 COST-EFFECTIVENESS OF SUTURELESS AORTIC VALVE REPLACEMENT VERSUS CONVENTIONAL AORTIC VALVE REPLACEMENT AND TRANSCATHETER AORTIC VALVE IMPLANTATION IN BRAZIL Coutinho, B.
22 S3 p. S562
 artikel
694 PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION Hill, N.
22 S3 p. S550
 artikel
695 PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE Ntaios, G.
22 S3 p. S550
 artikel
696 PCV56 COST-EFFECTIVENESS OF THE SUSTAINED-RELEASE PACLITAXEL-ELUTING ELUVIA STENT COMPARED TO THE PACLITAXEL-COATED ZILVER PTX STENT FOR ENDOVASCULAR TREATMENT OF PERIPHERAL ARTERY DISEASE: A GERMAN STATUTORY SICKNESS FUND PERSPECTIVE. Giretti, C.
22 S3 p. S551
 artikel
697 PCV55 COST-EFFECTIVENESS OF WARFARIN CARE BUNDLES AND NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION IN THAILAND Ng, S.S.
22 S3 p. S551
 artikel
698 PCV33 COST-EFFECTIVENESS OF WEARABLE CARDIOVERTER-DEFIBRILLATOR IN CHINA: A DECISION ANALYSIS Jiang, X.
22 S3 p. S547
 artikel
699 PCV112 COST UTILITY ANALYSIS OF TICAGRELOR REMOVAL BY CYTOSORB® IN PATIENTS REQUIRING EMERGENT OR URGENT CARDIAC SURGERY IN THE UK Javanbakht, M.
22 S3 p. S562
 artikel
700 PCV138 CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE PERIPHERAL ARTERY DISEASE QUALITY OF LIFE (PADQOL) QUESTIONNAIRE INTO HUNGARIAN: PILOTING RESULTS Horváth, L.
22 S3 p. S567
 artikel
701 PCV81 CURRENT TRENDS IN LIPID LOWERING THERAPY USE IN GERMANY Laufs, U.
22 S3 p. S556
 artikel
702 PCV147 DATA QUALITY EVALUATION OF 5 MUNICIPAL AND PROVINCIAL CLAIMS DATABASES OF FUJIAN PROVINCE IN CHINA Chen, C.
22 S3 p. S569
 artikel
703 PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS Owen, R.
22 S3 p. S563
 artikel
704 PCV123 DETERMINANTS OF POOR QUALITY OF LIFE AND HIGH HEALTH CARE RESOURCE CONSUMPTION IN HEART FAILURE PATIENTS IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY Afonso-Silva, M.
22 S3 p. S564
 artikel
705 PCV122 DETERMINING RISK THRESHOLDS FOR INITIATING STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A BENEFIT-HARM BALANCE MODELING STUDY Yebyo, H.
22 S3 p. S564
 artikel
706 PCV128 DEVELOPING AN EQ-5D-5L VALUE SET USING HEART DISEASE PATIENT'S PREFERENCES Gandhi, M.
22 S3 p. S565
 artikel
707 PCV125 DIFFERENCES ACROSS HEART FAILURE PATIENTS' CHARACTERISTICS, DISEASE EXPERIENCE AND QUALITY OF LIFE IN SHANGHAI COMPARED WITH REST OF CHINA Cristino, J.
22 S3 p. S564-S565
 artikel
708 PCV47 DOES THE COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN COMBINATION WITH STATIN THERAPY COMPARED TO STATIN ALONE DIFFER BETWEEN PRIMARY AND SECONDARY PREVENTION? Ademi, Z.
22 S3 p. S549
 artikel
709 PCV150 DO WEATHER CHANGES AFFECT THE RISK OF STROKE? AN ANALYSIS USING GERMAN CLAIMS DATA Ghiani, M.
22 S3 p. S570
 artikel
710 PCV68 ECONOMIC BURDEN OF ATHEROTROMBOTIC DISEASE IN THE CZECH REPUBLIC Hajickova, B.
22 S3 p. S553-S554
 artikel
711 PCV62 ECONOMIC EVALUATION AND NETWORK META-ANALYSIS OF NON-STATIN THERAPY AMONG STATIN-TREATED PATIENTS IN THAILAND Kongpakwattana, K.
22 S3 p. S552
 artikel
712 PCV10 EFFECT OF LOW PRIME VOLUME ON HEMATOCRIT IN CORONARY ARTERY BYPASS SURGERY Deák, A.
22 S3 p. S543
 artikel
713 PCV8 EFFICACY OF VENOUS EXERCISE FOR THE CHANGE OF VENOUS FLOW VELOCITY AMONG PREGNANT WOMEN Labádi, S.
22 S3 p. S542
 artikel
714 PCV83 EPIDEMIOLOGY OF STABLE CORONARY ARTERY DISEASE AND OF PERIPHERAL ARTERY DISEASE IN PORTUGAL Araújo, C.
22 S3 p. S556
 artikel
715 PCV148 ESTIMATE OF THE IMPACT AND COSTS OF CEREBROVASCULAR DISEASE FROM A HEALTH PLAN IN BRAZIL: REAL WORLD SCENARIO STUDY Reis Neto, J.P.
22 S3 p. S569
 artikel
716 PCV142 ESTIMATING THE IMPACT ON RECURRENT HOSPITAL ADMISSIONS AND AMBULATORY VISITS OF PRESCRIBING FERRIC CARBOXYMALTOSE IN IRON DEFICIENCY PATIENTS WITH CHRONIC HEART FAILURE: A RETROSPECTIVE RWE STUDY USING A HOSPITAL REGISTRY IN SPAIN Núñez, J.
22 S3 p. S568
 artikel
717 PCV7 ESTIMATION THE PHYSICAL ACTIVITY OF HEART FAILURE PATIENTS BASED ON TELEMETRY DATA Melczer, C.
22 S3 p. S542
 artikel
718 PCV139 EUROPEAN SURVEY ON STABLE ANGINA: REAL WORLD INSIGHTS ON PATIENTS’ CHARACTERISTICS, PERCEPTION OF DISEASE, AND QUALITY OF LIFE Heiman, F.
22 S3 p. S567
 artikel
719 PCV131 EVALUATION OF PRESCRIBING TRENDS AND ASSESSMENT OF DRUG RELATED PROBLEMS IN PATIENTS WITH ACUTE CORONARY SYNDROME Mandalapu, L.
22 S3 p. S566
 artikel
720 PCV121 EVALUATION OF THE EFFECTIVENESS OF A NATIONAL DISCHARGE PLANNING PROGRAM (PRADO) FOR HEART FAILLURE IN FRENCH HOSPITALS Vimont, A.
22 S3 p. S564
 artikel
721 PCV80 EVALUATION OF THE QUALITY OF LIFE OF PATIENTS WITH CARDIOVASCULAR DISEASES IN NUR-SULTAN, KAZAKHSTAN Bekbergenova, Z.
22 S3 p. S556
 artikel
722 PCV114 FEASIBILITY OF USING REAL WORLD EVIDENCE TO INFORM DECISIONS ON CONDUCTING A COST EFFECTIVENESS ANALYSIS: AN EXAMPLE OF STROKE RISK REDUCTION THERAPIES IN ATRIAL FIBRILLATION Saunders, O.
22 S3 p. S563
 artikel
723 PCV65 FEE FOR SERVICE VERSUS LUMP SUM PAYMENT: COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN GERMANY - PRIVATE INSURANCE VERSUS STATUTORY SICK FUNDS Wahler, S.
22 S3 p. S553
 artikel
724 PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE Kohls, M.
22 S3 p. S554
 artikel
725 PCV17 HEALTHCARE UTILIZATION PRIOR TO AN INITIAL DIAGNOSIS OF PAROXYSMAL SUPRVENTRICULAR TACHYCARDIA IN A LARGE HEALTHCARE SYSTEM Ludden, T.
22 S3 p. S544
 artikel
726 PCV38 HEALTH OUTCOMES PROJECTIONS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN A REAL-WORLD POPULATION IN PORTUGAL Afonso-Silva, M.
22 S3 p. S547-S548
 artikel
727 PCV107 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENT IN PATIENTS WITH HYPERTENSION IN HONG KONG (HK) SAR,CHINA Xu, R.H.
22 S3 p. S561
 artikel
728 PCV133 HETEROGENEITY IN PREFERENCES FOR ANTI-COAGULANT USE IN ATRIAL FIBRILLATION: A LATENT CLASS ANALYSIS van Til, J.A.
22 S3 p. S566
 artikel
729 PCV59 HOSPITAL LENGTH OF STAY AMONG VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH APIXABAN AND WARFARIN IN ENGLAND Carroll, R.
22 S3 p. S552
 artikel
730 PCV153 HOW COSTLY IS POOR ADHERENCE TO PHARMACOLOGICAL TREATMENTS FOR CARDIOVASCULAR DISEASE? A SYSTEMATIC LITERATURE REVIEW Monaco, A.
22 S3 p. S570-S571
 artikel
731 PCV13 INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE Kourlaba, G.
22 S3 p. S543
 artikel
732 PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION Kulikov, A.
22 S3 p. S554
 artikel
733 PCV20 MACHINE LEARNING BETTER PREDICTS RISK AFTER ACUTE CORONARY SYNDROMES, IDENTIFIES HIGH-COST INDIVIDUALS AND THOSE WITH ELEVATED BURDEN OF UNCONTROLLED RISK FACTORS de Carvalho, L.S.
22 S3 p. S545
 artikel
734 PCV113 MARKET ACCESS BARRIERS AND ADOPTION HURDLES FOR AI POWERED EHEALTH SOLUTIONS IN THE FIELD OF CARDIOLOGY Makin, D.
22 S3 p. S562
 artikel
735 PCV134 MOBILE HEALTH TECHNOLOGY PERCEPTIONS AND USER EXPERIENCE AMONG ATRIAL FIBRILLATION PATIENTS: A SOCIAL MEDIA LISTENING STUDY Halhol, S.
22 S3 p. S566
 artikel
736 PCV16 MULTIPLE STATISTICAL APPROACHES IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): THE EXAMPLE OF NAXOS, A LARGE FRENCH CER Belhassen, M.
22 S3 p. S544
 artikel
737 PCV66 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF ARTERIAL EMBOLISM AND THROMBOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Gazsó, T.
22 S3 p. S553
 artikel
738 PCV64 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF CARDIAC ARREST IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Gazsó, T.
22 S3 p. S553
 artikel
739 PCV4 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF HEART FAILURE IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Endrei, D.
22 S3 p. S542
 artikel
740 PCV135 OBSERVATIONAL, INTERNATIONAL, COHORT STUDY TO EVALUATE THE SATISFACTION AND PREFERENCES OF PATIENTS IN PREVENTIVE TREATMENT OF SECONDARY CARDIOVASCULAR EVENTS WITH A CARDIOVASCULAR POLYPILL Cosin-Sales, J.
22 S3 p. S566-S567
 artikel
741 PCV136 PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN Reed, S.D.
22 S3 p. S567
 artikel
742 PCV126 PATIENT PREFERENCES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW Gogna, S.
22 S3 p. S565
 artikel
743 PCV127 PATIENT PREFERENCES REGARDING ORAL ANTICOAGULANTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT IN SPANISH PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN-K ANTAGONISTS Mueller, S.
22 S3 p. S565
 artikel
744 PCV31 PATIENTS' PRODUCTIVITY LOSSES AND INFORMAL CARE COST RELATED TO ISCHEMIC STROKE IN RHONE AREA, FRANCE Barral, M.
22 S3 p. S546-S547
 artikel
745 PCV98 PCSK9 INHIBITORS: AN ANALYSIS OF CURRENT UPTAKE AND POTENTIAL OPPORTUNITIES IN ENGLAND Blaikie, T.
22 S3 p. S559
 artikel
746 PCV88 PHARMACY COLLECTION OF PRESCRIBED SECONDARY PREVENTIVE DRUG THERAPY AFTER MYOCARDIAL INFARCTION - A NORWEGIAN NATIONWIDE COHORT STUDY Jortveit, J.
22 S3 p. S557-S558
 artikel
747 PCV15 POTENTIAL IMPACT OF PROLONGED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR IN 'REAL WORLD' STABLE PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION VERSUS RANDOMIZED CONTROLLED TRIAL POPULATIONS Yan, B.
22 S3 p. S544
 artikel
748 PCV102 PRESCRIPTION PATTERN & PHYSICIAN PROPENSITY FOR CONGESTIVE HEART FAILURE TREATMENTS IN UNITED STATES & EUROPE Rusli, E.
22 S3 p. S560
 artikel
749 PCV79 PREVALENCE OF CARDIOVASCULAR DISEASES AND ASSOCIATED RISK FACTORS BY SEX AMONG ADULTS IN UNITED STATES Agrawal, N.
22 S3 p. S556
 artikel
750 PCV101 REAL-WORLD COST AND EFFECTIVENESS ANALYSIS OF POST-ACUTE CARE VS. NON-PAC FOR STROKE PATIENTS AFTER DISCHARGE FROM HOSPITAL Lang, H.C.
22 S3 p. S560
 artikel
751 PCV24 REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL Afonso-Silva, M.
22 S3 p. S545
 artikel
752 PCV151 REAL WORLD EVIDENCE OF THE EFFECT OF PERIPHERAL ARTERIAL DISEASE (PAD) ON PATIENT HEALTH OUTCOMES AND COSTS IN AUSTRALIA. Hegadekatti, N.
22 S3 p. S570
 artikel
753 PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY Sciattella, P.
22 S3 p. S557
 artikel
754 PCV124 REPORTING AND QUALITY OF PATIENT PREFERENCE STUDIES: A SYSTEMATIC LITERATURE REVIEW IN THE CARDIOVASCULAR DOMAIN Duenas, A.
22 S3 p. S564
 artikel
755 PCV93 RESOURCE USE AND COSTS OF ACUTE CORONARY SYNDROME: A LITERATURE REVIEW Sicras-Mainar, A.
22 S3 p. S558
 artikel
756 PCV111 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN CARDIOLOGY AND DIABETOLOGY Bellier, L.
22 S3 p. S562
 artikel
757 PCV90 RISK FACTORS, USE OF HEALTH CARE RESOURCES, AND MORTALITY IN PATIENTS WITH MINOR ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK Fasth, O.
22 S3 p. S558
 artikel
758 PCV34 RIVAROXABAN PLUS ASPIRIN FOR THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE Petersohn, S.
22 S3 p. S547
 artikel
759 PCV143 SACUBITRIL/VALSARTAN PRESCRIPTION PATTERNS AND TITRATION IN A REAL-WORLD SETTING IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY Afonso-Silva, M.
22 S3 p. S568
 artikel
760 PCV152 SELF-ASSESSED FUNCTIONAL CLASS, QUALITY OF LIFE AND HEALTHCARE RESOURCE CONSUMPTION IN PORTUGUESE HEART FAILURE PATIENTS: AN ANALYSIS OF THE PRIME STUDY Afonso-Silva, M.
22 S3 p. S570
 artikel
761 PCV129 SELF-ASSESSED FUNCTIONAL INSTRUMENT IN HEART FAILURE: CORRELATION WITH PATIENT REPORTED SYMPTOMS Guerreiro, J.P.
22 S3 p. S565
 artikel
762 PCV108 SIMULTANEOUS ATRIOVENTRICULAR JUNCTION ABLATION AND IMPLANTATION OF PERMANENT PACING DEVICE FOR PATIENTS WITH DRUG-REFRACTORY TACHYSYSTOLIC FORM OF ATRIAL FIBRILLATION Avdeyev, A.
22 S3 p. S561
 artikel
763 PCV115 SOME APPROACHES FOR THE ESTIMATION OF CENSORED PATIENT REPORTED OUTCOMES: RESULTS USING THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ) Kráľ, P.
22 S3 p. S563
 artikel
764 PCV140 STATIN UTILIZATION AND LIPID MANAGEMENT IN CHINESE NEWLY-ONSET ACUTE CORONARY SYNDROME PATIENTS UNDERGOING REVASCULARIZATION IN HONG KONG FROM 2004 TO 2017 Lee, V.
22 S3 p. S568
 artikel
765 PCV57 STUDY ON THE ATTRIBUTABLE COSTS OF VENOUS THROMBOEMBOLISM AND BLEEDINGS IN DENMARK. COMPARISON OF THE DIFFERENCE-IN-DIFFERENCE AND THE DIFFERENCE-IN-ACTUAL-COSTS METHODS Poulsen, P.B.
22 S3 p. S551
 artikel
766 PCV54 THE HEALTHCARE MANAGEMENT OF PATIENTS WITH THE CORONARY AND PERIPHERAL ARTERIAL DISEASES Ondrusova, M.
22 S3 p. S550-S551
 artikel
767 PCV85 THE LONG-TERM EFFECT OF PARTICULATE MATTER(PM2.5, PM10) ON INCIDENCE AND MORTALITY OF MYOCARDIAL INFARCTION(MI): A SYSTEMATIC LITERATURE REVIEW Kim, Y.
22 S3 p. S557
 artikel
768 PCV18 THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW Mitchell, C.R.
22 S3 p. S544
 artikel
769 PCV100 THE RELATIONSHIP BETWEEN PROCEDURAL VOLUME AND POSTOPERATIVE MORTALITY FOR PERCUTANEOUS CORONARY INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Walsh, K.
22 S3 p. S560
 artikel
770 PCV21 TIMI RISK SCORE IN PREDICTING IN HOSPITAL AND EARLY MORTALITY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY WOMEN:RESULTS FROM A DEVELOPING COUNTRY Furnaz, S.
22 S3 p. S545
 artikel
771 PCV58 TOTAL COSTS OF TREATMENT OF PATIENTS SUFFERING FROM VENOUS THROMBOEMBOLISM - IMPLICATIONS OF DIFFERENT COST PERSPECTIVES Nielsen, A.
22 S3 p. S551-S552
 artikel
772 PCV52 TRANSFERABILITY OF UK-BASED COST-EFFECTIVENESS MODEL TO HUNGARY, SWEDEN AND GERMANY: THE CASE OF MECHANICAL THROMBECTOMY BEYOND SIX HOURS FOLLOWING ADVANCED-IMAGING (VERSUS MECHANICAL THROMBECTOMY WITHIN SIX HOURS FOLLOWING CT+CTA) IN ACUTE ISCHAEMIC STROKE Peultier, A.C.
22 S3 p. S550
 artikel
773 PCV99 UNDERSTANDING POST DISCHARGE MANAGEMENT AFTER AN ACUTE MYOCARDIAL INFARCTION IN ITALY: REGIONAL PATHWAYS AND OUTCOME INDEX Mastrorilli, G.
22 S3 p. S559
 artikel
774 PCV149 UNHEALTHY WEEKENDS OR MONDAY BLUES? INVESTIGATING THE WEEKLY PATTERN OF STROKES Ghiani, M.
22 S3 p. S569-S570
 artikel
775 PCV116 USING ADMINISTRATIVE CLAIMS DATA TO ESTIMATE THERAPEUTIC INTENSITY IN MEDICALLY MANAGED HEART FAILURE PATIENTS Van Houten, J.
22 S3 p. S563
 artikel
776 PCV63 WHAT'S THE COST OF HOSPITALISATIONS DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES? Shamliyan, T.
22 S3 p. S552-S553
 artikel
777 PDB107 A COMPARISON BETWEEN THE EQ-5D-5L AND THE SF-6D IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Andayani, T.M.
22 S3 p. S592
 artikel
778 PDB4 A COST OFFSET ANALYSIS (COA) COMPARING REAL-TIME CONTINUOUS GLUCOSE MONITORING (RT-CGM) WITH INTERMITTENT SCANNING CONTINUOUS GLUCOSE MONITORING (IS-CGM) IN TYPE 1 DIABETES (T1D) SUBJECTS WITH IMPAIRED HYPOGLYCEMIA AWARENESS IN EIGHT COUNTRIES Minshall, M.E.
22 S3 p. S572
 artikel
779 PDB79 ADOPTION OF NEW DRUGS FOR TYPE 2 DIABETES MELLITUS: A QUALITATIVE STUDY WITH GREEK PHYSICIANS Karampli, E.
22 S3 p. S587
 artikel
780 PDB28 A HEALTH ECONOMIC AND DECISION MODELLING ANALYSIS PLAN FOR AN INTEGRATED DATABASE OF OVER 100 CLINICAL TRIALS MEASURING HYPOGLYCAEMIC ATTACKS FOR PEOPLE WITH DIABETES: A HEDMAP FOR HYPORESOLVE Brennan, A.
22 S3 p. S577
 artikel
781 PDB58 A LITERATRUE REVIEW OF THE ECONOMIC BURDEN OF HYPOGLYCEMIA IN PATIENTS WITH DIABETES MELLITUS IN CHINA Wu, J.H.
22 S3 p. S583
 artikel
782 PDB83 ANALYSIS OF PRESCRIPTION RATES OF INSULIN GLARGINE (IG), PER PRODUCT AND PRESENTATION TYPE, BY GENERAL PRACTITIONERS (GP) IN ENGLAND AND ITS ASSOCIATION WITH HEALTH DETERMINANTS (2013-2018) Agirrezabal, I.
22 S3 p. S588
 artikel
783 PDB128 A NATIONWIDE, OBSERVATIONAL STUDY ASSESSING ADHERENCE TO THE HELLENIC GUIDELINES FOR FOLLOW-UP, CLINICAL, AND LABORATORY EVALUATIONS, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE GLANCE™ STUDY Papanas, N.
22 S3 p. S595-S596
 artikel
784 PDB91 AN MCDA APPROACH IN THE EVALUATION OF NEW TECHNOLOGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT Nascimento, A.
22 S3 p. S589
 artikel
785 PDB34 A PERSONALIZED SCREENING STRATEGY FOR DIABETIC RETINOPATHY: A COST-EFFECTIVENESS PERSPECTIVE Emamipour, S.
22 S3 p. S578
 artikel
786 PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ΜCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT Beiderbeck, A.
22 S3 p. S574
 artikel
787 PDB68 ASSESSMENT OF RISK FOR DEVELOPMENT OF TYPE 2 DIABETES IN THE GREEK POPULATION Naoum, P.
22 S3 p. S585
 artikel
788 PDB71 ASSOCIATION OF SEVERE HYPOGLYCEMIA WITH ALL-CAUSE MORTALITY AND COMPLICATIONS AMONG PATIENTS WITH DIABETES MELLITUS IN CHINA Zhang, J.
22 S3 p. S585-S586
 artikel
789 PDB37 A SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF COST-EFFECTIVENESS ANALYSIS OF INSULIN PUMPS COMPARED WITH MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS Adil, M.
22 S3 p. S578-S579
 artikel
790 PDB93 BOOTSTRAPPING USED TO ESTIMATE CONFIDENCE INTERVAL (CI) WITH INVERSE PROBABILITY TREATMENT WEIGHTING METHOD (IPTW) ON PROPENSITY SCORE (PS) IN A REAL WORLD STUDY Niarra, R.
22 S3 p. S589-S590
 artikel
791 PDB127 BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL Busch, J.
22 S3 p. S595
 artikel
792 PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION Yagudina, R.
22 S3 p. S575
 artikel
793 PDB53 BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS TYPE II IN RUSSIA Boltyenkov, A.T.
22 S3 p. S582
 artikel
794 PDB88 BUDGET IMPACT OF USING PEGVISOMANT FOR TREATMENT OF ACROMEGALY IN RUSSIA Avxentyev, N.A.
22 S3 p. S588-S589
 artikel
795 PDB124 BURDEN OF HEART FAILURE IN PATIENTS WITH DIABETES IN ENGLAND Raza, S.
22 S3 p. S595
 artikel
796 PDB109 BURDEN OF ILLNESS ASSOCIATED WITH HYPERPHAGIA AND SEVERE OBESITY Estrada, E.
22 S3 p. S592
 artikel
797 PDB70 CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY TREATED WITH BASAL INSULIN THERAPY: A POPULATION-BASED UK STUDY Adan, M.
22 S3 p. S585
 artikel
798 PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY Chang, K.C.
22 S3 p. S573
 artikel
799 PDB1 COMPARISON OF NONINVASIVE SCORES FOR THE PREDICTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG METABOLIC SYNDROME PATIENTS Phisalprapa, P.
22 S3 p. S572
 artikel
800 PDB48 COST AND CAPACITY EFFECTS OF HEALTHYWEIGHTHUB @ VIRTUAL HOSPITAL 2.0 IN FINLAND Väätäinen, S.
22 S3 p. S581
 artikel
801 PDB10 COST ASSOCIATED WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS IN TWO TERTIARY HEALTHCARE FACILITIES IN A RESOURCE-LIMITED SETTING Ipingbemi, A.
22 S3 p. S573
 artikel
802 PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA Choon, W.Y.
22 S3 p. S580
 artikel
803 PDB89 COST-EFFECTIVENES ANALYSIS OF USING PEGVISOMANT FOR TREATMENT OF ACROMEGALY IN RUSSIA Avxentyev, N.A.
22 S3 p. S589
 artikel
804 PDB42 COST-EFFECTIVENESS ANALYSIS FOR HBA1C TEST INTERVALS IN PATIENTS ON TREATMENT FOR STABLE TYPE 2 DIABETES Ohde, S.
22 S3 p. S579-S580
 artikel
805 PDB44 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA Ming, J.
22 S3 p. S580
 artikel
806 PDB55 COST-EFFECTIVENESS ANALYSIS OF NONINVASIVE SCORES FOR THE SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG METABOLIC SYNDROME PATIENTS Phisalprapa, P.
22 S3 p. S582
 artikel
807 PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION Yagudina, R.
22 S3 p. S577
 artikel
808 PDB64 COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE Wu, B.
22 S3 p. S584
 artikel
809 PDB14 COST-EFFECTIVENESS OF CONTRAVE® IN OBESITY MANAGEMENT IN CANADA Nuijten, M.
22 S3 p. S574
 artikel
810 PDB35 COST-EFFECTIVENESS OF GLICLAZIDE MR-BASED INTENSIVE GLUCOSE CONTROL VERSUS STANDARD GLUCOSE CONTROL IN TYPE 2 DIABETES MELLITUS. AN ECONOMIC ANALYSIS IN VIETNAM OF THE ADVANCE TRIAL Ethgen, O.
22 S3 p. S578
 artikel
811 PDB25 COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN Saiyarsarai, P.
22 S3 p. S576
 artikel
812 PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT) Evans, M.
22 S3 p. S583
 artikel
813 PDB63 COST-EFFECTIVENESS OF INSULIN PUMP AND CONTINUES GLUCOSE MONITORING VERSUS MULTIPLE DAILY INJECTIONS AND SELF-MONITORING OF BLOOD GLUCOSE IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS Djalalov, S.
22 S3 p. S584
 artikel
814 PDB92 COST-EFFECTIVENESS OF TELEMEDICINE FOR THE MANAGEMENT OF DIABETES MELLITUS: A SYSTEMATIC LITERATURE REVIEW Adil, M.
22 S3 p. S589
 artikel
815 PDB33 COST-EFFECTIVENESS OF THE PDM-PROVALUE STUDY PROGRAM IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE GERMAN STATUTORY HEALTHCARE PERSPECTIVE Sailer, F.
22 S3 p. S578
 artikel
816 PDB132 COST-EFFECTIVENESS OF THROMBOLYSIS WITH ALTEPLASE IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN SLOVAKIA Blazinska, L.
22 S3 p. S596
 artikel
817 PDB12 COST-MINIMIZATION ANALYSIS OF INSULIN LISPRO 50/50 VERSUS INSULIN ASPART 30/70 PREMIXED FORMULATIONS IN TYPE II DIABETES Yousefi, N.
22 S3 p. S573-S574
 artikel
818 PDB38 COST OF ANTI-DIABETIC MEDICATIONS AMONG TYPE II DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY IN SOUTH INDIA Thomas, S.
22 S3 p. S579
 artikel
819 PDB120 COSTS AND RESOURCE USE ASSOCIATED WITH SEVERE HYPOGLYCEMIC EVENTS IN PATIENTS WITH DIABETES IN IRAN Ghaffari, S.
22 S3 p. S594
 artikel
820 PDB57 COST SAVINGS ASSOCIATED WITH PREMIX VERSUS BASAL-BOLUS REGIMEN IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED UNDER BASAL INSULIN REGIMEN Sellam, Y.
22 S3 p. S583
 artikel
821 PDB123 CURRENT STATUS AND USE OF RESOURCES OF LYSOSOMAL STORAGE DISEASES: ANALYSIS OF A SPANISH CLAIMS DATABASE Darba, J.
22 S3 p. S595
 artikel
822 PDB72 DEPRIVATION - MAIN CAUSE OF DIABETIC FOOT ULCER IN GERMANY Wahler, S.
22 S3 p. S586
 artikel
823 PDB75 DIABETES MEDICATION MANAGEMENT IN SLOVENIA FROM THE PERSPECTIVE OF PRESCRIBERS AND REPRESENTATIVES OF REGULATORY BODIES Zerovnik, S.
22 S3 p. S586
 artikel
824 PDB80 DIABETIC MACULAR EDEMA IN EUROPE: THE IMPACT OF PAYER POLICY ON PRESCRIBING Privolnev, Y.
22 S3 p. S587
 artikel
825 PDB106 DOES MOBILE HEALTH LIVE UP TO EXPECTATIONS? EXPLORING REAL-WORLD EXPERIENCES IN PATIENTS WITH DIABETES Booth, A.
22 S3 p. S591-S592
 artikel
826 PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS? McEwan, P.
22 S3 p. S581
 artikel
827 PDB52 ECONOMIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW Shaikh, J.
22 S3 p. S582
 artikel
828 PDB130 ECONOMIC BURDEN OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR THERAPIES: ANALYSIS OF NATIONAL SPECIALTY PHARMACY DATABASE Mehta, Z.
22 S3 p. S596
 artikel
829 PDB69 ECONOMIC BURDEN OF TYPE 2 DIABETES (T2D) IN EMERGING AND ESTABLISHED MARKETS: DATA FROM THE G15 REVIEW Lopes, R.
22 S3 p. S585
 artikel
830 PDB54 ECONOMIC EVALUATION OF A NEW POLYGENIC RISK SCORE TO PREVENT NEPHROPATHIES IN TYPE-2 DIABETIC PATIENTS Guinan, K.
22 S3 p. S582
 artikel
831 PDB56 ECONOMIC IMPACT OF TYPE 2 DIABETES AND DIABETES-ASSOCIATED COMPLICATIONS: A LARGE CLAIMS-BASED STUDY Hajickova, B.
22 S3 p. S582-S583
 artikel
832 PDB111 EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE Sharma, V.
22 S3 p. S592-S593
 artikel
833 PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS Carrasco Perez, M.
22 S3 p. S575
 artikel
834 PDB59 EVALUATING THE COST-UTILITY OF ADDING SODIUM-GLUCOSE COTRANSPORTER INHIBITORS TO A BASAL-BOLUS INSULIN REGIMEN IN PATIENTS WITH TYPE 1 DIABETES IN THE UK: AN ANALYSIS USING THE PRIME DIABETES MODEL Pollock, R.
22 S3 p. S583
 artikel
835 PDB13 EVALUATING THE ECONOMIC AND HUMANISTIC BURDEN OF TYPE 2 DIABETES MELLITUS IN EMERGING MARKETS COMPARED TO ESTABLISHED MARKETS Anstee, K.
22 S3 p. S574
 artikel
836 PDB36 EVALUATING THE IMPACT OF INSULIN PRICE FLUCTUATION IN THE USA ON THE HEALTHCARE EXPENDITURE IN T2DM De Cristofano, F.
22 S3 p. S578
 artikel
837 PDB100 EXAMINING THE TEMPORAL TRENDS IN HYPOGLYCEMIA EVENTS, TREATMENT ADHERENCE AND A1C IN PATIENTS WITH T2D IN THE US Nicholls, C.
22 S3 p. S591
 artikel
838 PDB112 EXPERIENCES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS PATIENTS IN THE KINGDOM OF SAUDI ARABIA Strizek, A.A.
22 S3 p. S593
 artikel
839 PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN Norrbacka, K.
22 S3 p. S594
 artikel
840 PDB81 HEALTHCARE RESOURCE USE ASSOCIATED WITH TYPE 2 DIABETES IN AFRICA, EURASIA, THE MIDDLE-EAST AND SOUTH-ASIA: RESULTS FROM THE 7TH WAVE OF THE INTERNATIONAL DIABETES MANAGEMENT PRACTICE STUDY (IDMPS) Le Nouveau, P.
22 S3 p. S587-S588
 artikel
841 PDB17 HEALTH ECONOMIC EFFECTS OF THE UPDATED FOOT ULCER SUBMODEL IN THE IQVIA CORE DIABETES MODEL Monteiro, S.
22 S3 p. S575
 artikel
842 PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D) Balijepalli, C.
22 S3 p. S572
 artikel
843 PDB46 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): PRODUCTIVITY LOSS AND INDIRECT COSTS Ferreira, J.
22 S3 p. S580
 artikel
844 PDB45 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): RESOURCE USE AND DIRECT COSTS Ferreira, J.
22 S3 p. S580
 artikel
845 PDB11 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): TOTAL COSTS Ferreira, J.
22 S3 p. S573
 artikel
846 PDB47 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS) VS. HIPOS-ER (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - EMERGENCY ROOM) - A COMPARISON OF THE ECONOMIC OUTCOMES Ferreira, J.
22 S3 p. S581
 artikel
847 PDB41 HOW ECONOMIC ANALYSIS INCREASE AWARENESS ON CLINICAL SERVICE, A CASE OF DIABETES MELLITUS AT A TEACHING HOSPITAL IN MYANMAR Oo, W.W.
22 S3 p. S579
 artikel
848 PDB103 HUMANISTIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW Shaikh, J.
22 S3 p. S591
 artikel
849 PDB76 IMPACT OF COPAYMENT INCREASE OF ANTIDIABETIC MEDICATIONS ON GLYCAEMIC CONTROL IN FINNISH PATIENTS WITH TYPE 2 DIABETES Lavikainen, P.
22 S3 p. S586-S587
 artikel
850 PDB39 INSULIN PRICE FLUCTUATION IN THE USA BETWEEN JULY 2017 AND JULY 2019 De Cristofano, F.
22 S3 p. S579
 artikel
851 PDB90 IS IT POSSIBLE TO AUTOMATE A SYSTEMATIC LITERATURE REVIEW? Xia, A.
22 S3 p. S589
 artikel
852 PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM) Moldaver, D.
22 S3 p. S572-S573
 artikel
853 PDB67 MAIN PREDICTORS OF DIABETES MELLITUS TYPE 2 (DM2T) IN THE RUSSIAN FEDERATION Shestakova, M.
22 S3 p. S585
 artikel
854 PDB84 MANAGEMENT OF PREDIABETES FROM THE PERSPECTIVE OF SPANISH PHYSICIANS AND COMMUNITY PHARMACISTS. DETECTA2 STUDY Franch-Nadal, J.
22 S3 p. S588
 artikel
855 PDB27 ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS Alabdulkarim, H.
22 S3 p. S576-S577
 artikel
856 PDB118 OUTCOMES AND HEALTHCARE COSTS FOR PATIENTS WITH TYPE 2 DIABETES UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN: A NATIONWIDE OBSERVATIONAL STUDY Norhammar, A.
22 S3 p. S594
 artikel
857 PDB117 PATIENT TREATMENT SATISFACTION AND STUDY STAFF PERCEPTIONS OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES Hansen, B.B.
22 S3 p. S593-S594
 artikel
858 PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS Ofori-Asenso, R.
22 S3 p. S591
 artikel
859 PDB21 PREDICTING HEALTHCARE COSTS OF DIABETES USING MACHINE LEARNING MODELS Gonzalez Rodriguez, J.
22 S3 p. S575
 artikel
860 PDB125 PREDICTING NASH PATIENTS USING INNOVATIVE MACHINE LEARNING TECHNIQUES Docherty, M.
22 S3 p. S595
 artikel
861 PDB40 PREDICTIVE ANALYSIS OF COST AND CAPACITY EFFECTS OF THE DIGITALIZED SECONDARY CARE SERVICES FOR INSULIN-DEPENDENT DIABETES PATIENTS @ VIRTUAL HOSPITAL 2.0 Soini, E.
22 S3 p. S579
 artikel
862 PDB94 PREDICTIVE MODELS USING MACHINE LEARNING FOR MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC LITERATURE REVIEW Xu, Q.
22 S3 p. S590
 artikel
863 PDB65 PRETRIAL MODELLING METHODS TO JUSTIFY AND INFORM THE DESIGN OF LARGE RCTS - EXPECTED VALUE OF SAMPLE INFORMATION FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT Pollard, D.
22 S3 p. S584
 artikel
864 PDB51 PREVENTION AS A PUBLIC HEALTH MEASURE: LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF A POPULATION-BASED IODINE DEFICIENCY DISEASES PREVENTION PROGRAM Rochau, U.
22 S3 p. S581-S582
 artikel
865 PDB129 PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS IN PEOPLE WITH HEPATIC ENCEPHALOPATHY IN ENGLAND Holden, S.
22 S3 p. S596
 artikel
866 PDB24 REAL WORLD DATA ANALYSIS OF HEALTHCARE RESOURCE USE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE Vivas Consuelo, D.
22 S3 p. S576
 artikel
867 PDB122 REAL-WORLD INSULIN THERAPY IN GERMAN TYPE 2 DIABETES MELLITUS PATIENTS: PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND INSULIN DOSAGE Gabler, M.
22 S3 p. S594-S595
 artikel
868 PDB73 RELATIONSHIP BETWEEN METABOLIC SYNDROME RISK LEVEL, BODY COMPOSITION AND LIPID PROFILE AMONG ADULTS IN MONGOLIA Yoo, J.Y.
22 S3 p. S586
 artikel
869 PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM) Willis, M.
22 S3 p. S590
 artikel
870 PDB9 SERUM GGT AND HSCRP: EARLY PREDICTORS OF OXIDATIVE STRESS AND INFLAMMATION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH GOOD AND POOR GLYCEMIC CONTORL M, B.S.
22 S3 p. S573
 artikel
871 PDB23 SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA Jendle, J.
22 S3 p. S575-S576
 artikel
872 PDB102 TARGETED LITERATURE REVIEW INTO METHODS OF DETERMINING PATIENTS' PREFERENCE FOR TREATMENT TYPE IN DIABETES Collings, H.
22 S3 p. S591
 artikel
873 PDB19 THE BIAS OF IGNORING CARDIOPROTECTIVE EFFECTS IN COST-EFFECTIVENESS ANALYSIS IN DIABETES Fridhammar, A.
22 S3 p. S575
 artikel
874 PDB26 THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS Maas, C.
22 S3 p. S576
 artikel
875 PDB61 THE CLINICAL AND ECONOMIC IMPACT OF ADDING AN ADHERENCE MODULE TO THE IQVIA CORE DIABETES MODEL Ramos, M.
22 S3 p. S584
 artikel
876 PDB66 THE COST OF COMPLICATIONS OF TYPE 2 DIABETES (T2D) IN ESTABLISHED AND EMERGING MARKETS: ESTIMATES FROM THE G15 REVIEW Lopes, R.
22 S3 p. S584-S585
 artikel
877 PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS de Jong, L.
22 S3 p. S574
 artikel
878 PDB97 THE EFFECT OF NIGHT EATING ON NUTRITIONAL HABITS AND QUALITY OF LIFE OF DIABETIC PATIENTS Pakai, A.
22 S3 p. S590
 artikel
879 PDB121 THE FINANCIAL IMPACT OF FEBUXOSTAT REIMBURSEMENT TO THE TAIWAN NATIONAL HEALTH INSURANCE Liu, P.J.
22 S3 p. S594
 artikel
880 PDB96 THE IMPACT OF ADJUNCT DAPAGLIFLOZIN ON TREATMENT SATISFACTION IN TYPE 1 DIABETES MELLITUS Gordon, J.
22 S3 p. S590
 artikel
881 PDB30 THE INDIRECT COSTS OF DIABETES MELLITUS IN THE SLOVAK REPUBLIC Suchansky, M.
22 S3 p. S577
 artikel
882 PDB131 THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND Koski, L.
22 S3 p. S596
 artikel
883 PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS Sapin, H.
22 S3 p. S588
 artikel
884 PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE Boye, K.
22 S3 p. S593
 artikel
885 PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS García-Pérez, L.E.
22 S3 p. S593
 artikel
886 PDB49 THE RELATIONSHIP BETWEEN HBA1C REDUCTION AND COSTS: A COHORT STUDY OF PATIENTS WITH TYPE 2 DIABETES Lage, M.
22 S3 p. S581
 artikel
887 PDB110 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM PATIENTS' PERSPECTIVE Chen, T.
22 S3 p. S592
 artikel
888 PDB108 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM THE PERSPECTIVE OF HEALTHCARE PROVIDERS (HCPS) Chen, T.
22 S3 p. S592
 artikel
889 PDB31 TRENDS IN THE USES OF ANTI-OSTEOPOROTIC DRUGS IN TAIWAN FROM 2012 TO 2018 Liu, C.P.
22 S3 p. S577
 artikel
890 PDB99 UNDERSTANDING THE HUMANISTIC BURDEN AND PATIENT IMPACT IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) Oliver, L.
22 S3 p. S590-S591
 artikel
891 PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH) Ratziu, V.
22 S3 p. S586
 artikel
892 PDB2 USING REAL WORLD DATA TO EXAMINE TRIGLYCERIDES, LDL-CHOLESTEROL, AND HDL-CHOLESTEROL AS PREDICTORS OF PROGRESSION FROM NONALCOHOLIC STEATOHEPATITIS TO HEPATOCELLULAR CANCER AND LIVER CIRRHOSIS Kuranz, S.
22 S3 p. S572
 artikel
893 PDB77 WILSON'S DISEASE: COST OF HOSPITALIZATION IN GERMANY Wahler, S.
22 S3 p. S587
 artikel
894 PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS? Metry, A.
22 S3 p. S577-S578
 artikel
895 PDG110 A BUYERS' CLUB TO IMPROVE ACCESS TO HEPATITIS C AND HIV TREATMENT FOR VULNERABLE POPULATIONS Vernaz, N.
22 S3 p. S615
 artikel
896 PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM Ravindra Reddy, N.
22 S3 p. S613
 artikel
897 PDG89 ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) MARKET ACCESS - A CONTINUING CHALLENGE Watson, C.
22 S3 p. S612
 artikel
898 PDG53 A FOCUS GROUP STUDY TO IDENTIFY THE FACTORS INFLUENCING PRIORITY SETTING IN HEALTHCARE: FOCUSING ON AGE AND SEVERITY Bae, G.
22 S3 p. S605
 artikel
899 PDG36 ANALYSIS OF GABAPENTINOIDS ABUSE IN THE MIDDLE EAST AND NORTH AFRICA REGION UTILIZING THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENTS REPORTING SYSTEM DATABASE Alsheikh, M.Y.
22 S3 p. S602
 artikel
900 PDG74 AN ANALYSIS OF RESTRICTED RECOMMENDATIONS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) Rahman, M.
22 S3 p. S609
 artikel
901 PDG48 AN ANALYSIS OF THE DANISH MODEL FOR ANALOGUE COMPETITION OF HOSPITAL MEDICINE BASED ON THE THERAPEUTIC AREA, HEPATITIS C Christensen, E.
22 S3 p. S604
 artikel
902 PDG3 ANTI-VEGF DRUGS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - A SYSTEMATIC REVIEW OF THE IMPACT OF ANTI-VEGF THERAPY ON REDUCING BLINDNESS AND VISUAL IMPAIRMENT Carrasco, J.
22 S3 p. S597
 artikel
903 PDG27 ARE ACUTE THERAPIES AND CURATIVE DRUGS MORE AFFORDABLE THAN CHRONIC TREATMENTS IN RARE DISEASES? AN ANALYSIS OF THE TOP 20 MOST EXPENSIVE DRUGS IN THE US Craddy, P.
22 S3 p. S601
 artikel
904 PDG43 ARE PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS AGREEMENTS ESSENTIAL FOR NICE TO RECOMMEND ACCESS? A COMPARISON OF ONCOLOGY AND NON-ONCOLOGY APPRAISALS Chunara, F.
22 S3 p. S603
 artikel
905 PDG87 ARE VALUE ASSESSMENT FRAMEWORKS USING RWE? A REVIEW OF NICE AND ICER PSORIASIS ASSESSMENTS Jaksa, A.
22 S3 p. S611
 artikel
906 PDG63 ASSESMENT OF ACCESS TO INNOVATIVE MEDICINES IN UKRAINE Babak, N.
22 S3 p. S607
 artikel
907 PDG71 A STUDY OF PHARMACIST'S LEVEL OF AWARENESS ABOUT FIRST REIMBURSEMENT PROGRAM IN UKRAINE Zaliska, O.
22 S3 p. S608
 artikel
908 PDG6 A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (NMA) OF CRISABOROLE 2% OINTMENT FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS (AD) Fahrbach, K.
22 S3 p. S597-S598
 artikel
909 PDG56 BIOSIMILAR MARKET DYNAMICS IN KOREA Kim, H.
22 S3 p. S606
 artikel
910 PDG23 BUDGET IMPACT ANALYSIS OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF GEP-NET AND ACROMEGALY IN THE UK Feuilly, M.
22 S3 p. S600
 artikel
911 PDG61 CANCER DRUGS SHORTAGES IN ROMANIA: MAGNITUDE, CAUSES AND SOLUTIONS Mixich, V.
22 S3 p. S607
 artikel
912 PDG13 CAN THE PURCHASING PERFORMANCE OF HEALTHCARE INSTITUTIONS BE ASSESSED VIA THE DATA DECLARED FOR REIMBURSEMENT? Tano, M.
22 S3 p. S599
 artikel
913 PDG19 CHARACTERISTICS AND HEALTHCARE SERVICE USE OF PATIENTS WITH SCHIZOPHRENIA SWITCHING FROM ORAL TO LONG-ACTING INJECTABLE ANTIPSYCHOTICS Wing, V.
22 S3 p. S600
 artikel
914 PDG102 CLINICAL OUTCOMES COMPARING CLOPIDOGREL AND PRASUGREL/ TICAGRELOR IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA Lam, A.
22 S3 p. S614
 artikel
915 PDG108 CLINICAL OUTCOMES ON SWITCHING BETWEEN NEWER P2Y12 RECEPTOR INHIBITORS AND CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA Lam, A.
22 S3 p. S614-S615
 artikel
916 PDG52 CONSISTENCY OF NEW DRUG PRICING IN KOREA: BRIDGING VARIATIONS AMONG PERSONNEL IN PRICE NEGOTIATIONS Kwon, H.Y.
22 S3 p. S605
 artikel
917 PDG18 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN TREATING NAMD IN CHINA Fan, C.S.
22 S3 p. S599-S600
 artikel
918 PDG11 COST-EFFECTIVENESS OF AN INJECTABLE FLUOCINOLONE ACETONIDE OCULAR IMPLANT FOR PREVENTION OF RELAPSE IN RECURRENT NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE Beiderbeck, A.
22 S3 p. S598-S599
 artikel
919 PDG31 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS LASER PHOTOCOAGULATION OR OBSERVATION FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION: FROM CHINESE SOCIETAL PERSPECTIVE He, X.
22 S3 p. S602
 artikel
920 PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE LIU, J.
22 S3 p. S601
 artikel
921 PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY Silva Miguel, L.
22 S3 p. S611-S612
 artikel
922 PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY Rotundo, M.
22 S3 p. S599
 artikel
923 PDG104 DECREASING NUMBER OF PRESCRIPTIONS AFTER THEY BECAME MANDATORY AND THEIR VALIDITY PERIOD WAS EXTENDED TO TWO YEARS: CASE FINLAND SINCE 2017 Jormanainen, V.
22 S3 p. S614
 artikel
924 PDG69 DEVELOPMENT OF LISTS OF TOPICAL ANTIFUNGAL DRUGS INCLUDED INTO THE ALL EDITIONS OF STATE FORMULARY OF UKRAINE Vashchenko, O.
22 S3 p. S608
 artikel
925 PDG46 DOES NEW WAY TO IMPROVE PATIENTS ACCESS TO EXPENSIVE INNOVATIVE DRUGS IN POLAND WORK? Maciejewska, K.
22 S3 p. S604
 artikel
926 PDG57 DRUG PRICING PREDICTABILITY IN FRANCE: WHICH MANAGED ENTRY AGREEMENT SUITS THE BEST? Moutie, A.S.
22 S3 p. S606
 artikel
927 PDG107 DRUG SURVIVAL OF BIOLOGICAL THERAPIES FOR ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE Yu, C.L.
22 S3 p. S614
 artikel
928 PDG81 EARLY HEALTH TECHNOLOGY ASSESSMENT (HTA): LESSONS LEARNED FROM A RUSSIAN BIOTECHNOLOGY COMPANY Tolkacheva, D.
22 S3 p. S610
 artikel
929 PDG25 ECONOMIC BURDEN OF OPIOID ABUSE IN THE USA Bhattacharyya, M.
22 S3 p. S601
 artikel
930 PDG86 ECONOMIC EVALUATION FOR PRICING AND REIMBURSEMENT OF NEW DRUGS IN SPAIN: FABLE OR DESIDERATUM? Epstein, D.
22 S3 p. S611
 artikel
931 PDG41 ECONOMIC IMPACT OF INDUSTRY-SPONSORED CLINICAL TRIALS OF MEDICINAL PRODUCTS ON THE PHARMACEUTICAL SECTOR IN AUSTRIA Walter, E.
22 S3 p. S603
 artikel
932 PDG106 EFFECTS OF STATIN THERAPY ON LONG-TERM HEALTH CARE OUTCOMES AND MEDICAL COST-BASED ON CHINA REGIONAL HEALTH INSURANCE CLAIM DATABASE Chen, C.
22 S3 p. S614
 artikel
933 PDG15 EFFICIENCY AND PRODUCTION OF THE AREA OF PREPARATION OF INTRAVENOUS ADMIXTURES AND STERILE MEDICATIONS Feal-Cortizas, B.
22 S3 p. S599
 artikel
934 PDG20 GLOBAL COMPARISON AND META-ANALYSIS OF INCREMENTAL COST-EFFECTIVENESS (ICER) FOR NEW CANCER DRUGS Oliveira, F.A.O.
22 S3 p. S600
 artikel
935 PDG17 HOSPITAL COSTS ASSOCIATED WITH THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE IN HUNGARY Vajda, P.
22 S3 p. S599
 artikel
936 PDG78 IMPACT OF FIRST RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) FROM EUNETHTA ON DRUG HTA ASSESSMENTS BY HAS, IQWIG AND NICE Ferreira, P.
22 S3 p. S610
 artikel
937 PDG10 IMPROVING THE BUSINESS MODEL OF VALUE ADDED MEDICINES: NEW VALUE ASSESSMENT FRAMEWORK IS NEEDED Petykó, Z.
22 S3 p. S598
 artikel
938 PDG73 INCLUSION OF ADVERSE EVENTS IN THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: A REVIEW OF THE MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS) LAM, L.
22 S3 p. S609
 artikel
939 PDG80 INFLUENCING FACTORS FOR A RENEWED BENEFIT ASSESSMENT IN THE GERMAN HTA PROCESS - A COMPARATIVE OVERVIEW OF §13 AND §14 IN CHAPTER 5 OF THE G-BA RULES OF PROCEDURE Bonduelle, D.
22 S3 p. S610
 artikel
940 PDG54 INTERNATIONAL COMPARISON OF ORPHAN DRUG POLICY EFFECT ON ORPHAN DRUG EXPENDITURE Kang, D.
22 S3 p. S605
 artikel
941 PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT? Mechelke, M.
22 S3 p. S609
 artikel
942 PDG7 IS GERMANY GOING TO OPEN-UP FOR OUTCOMES-BASED AGREEMENTS? Caban, A.
22 S3 p. S598
 artikel
943 PDG44 JOINT HTA AND DRUG PRICING COLLABORATIONS IN EU: BY WHOM AND WHEN TO BE PURSUED? Middelburg, E.
22 S3 p. S603-S604
 artikel
944 PDG72 KEY CRITERIA FOR ACCEPTANCE OF INDIRECT COMPARISONS IN THE BENEFIT ASSESSMENT BY THE G-BA AND BY THE IQWIG Bonduelle, D.
22 S3 p. S608-S609
 artikel
945 PDG70 KNOWLEDGE, ATTITUDES AND PRACTICES OF MOROCCAN COMMUNITY PHARMACISTS TOWARDS THE THIRD-PARTY PAYER SYSTEM Ahid, S.
22 S3 p. S608
 artikel
946 PDG2 METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING PALLIATIVE CARE: A SYSTEMATIC REVIEW Szydziak, K.
22 S3 p. S597
 artikel
947 PDG51 OPTIMIZING CHINA BMI FUNDS THROUGH DRUG VOLUME-BASED PROCUREMENT: UNDERSTANDING THE RESULT, IMPACT AND CHALLENGES He, Y.
22 S3 p. S605
 artikel
948 PDG29 ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION Bodaghi, C.
22 S3 p. S601
 artikel
949 PDG91 OUTLYING STUDIES CAN CHANGE RANKING OF TREATMENTS AND COMPARATIVE EFFICACY ESTIMATES IN NETWORK META-ANALYSIS: FROM A COMPARATIVE STUDY OF ANTIHYPERTENSIVE DRUGS Nakamura, R.
22 S3 p. S612
 artikel
950 PDG100 PARENTERAL PREPARATIONS STEWARDSHIP IN A TEACHING HOSPITAL IN NIGERIA Ogbonna, B.O.
22 S3 p. S613
 artikel
951 PDG99 PATIENT'S PREFERENCES REGARDING DIRECT ORAL ANTICOAGULANTS SELECTION: RELEVANT CRITERIA FOR ROUTINE CLINICAL DECISION MAKING? Marzo, C.
22 S3 p. S613
 artikel
952 PDG67 PERCEPTION OF UKRAINIAN PHARMACISTS REGARDING ANTIFUNGAL NAIL LACQUERS Vashchenko, O.
22 S3 p. S608
 artikel
953 PDG83 PHARMACEUTICAL PRICING: LAUNCH STRATEGY RULES? ANALYSIS OF GERMAN DATA Lamping, C.
22 S3 p. S610-S611
 artikel
954 PDG50 PHARMACEUTICAL PRICING POLICIES IN QATAR AND LEBANON: NARRATIVE REVIEW AND DOCUMENT ANALYSIS Mohamed Ibrahim, M.I.
22 S3 p. S605
 artikel
955 PDG30 PHARMACOECONOMIC EVALUATION OF ANTI-VEGF DRUGS AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CHINA Liu, J.
22 S3 p. S601-S602
 artikel
956 PDG35 RACE, SLEEP TESTING, AND TREATMENT DIFFERENCES BETWEEN NARCOLEPTIC PEDIATRIC POPULATIONS WITH AND WITHOUT CATAPLEXY: A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK ANALYSIS Blumberg, P.B.
22 S3 p. S602
 artikel
957 PDG37 REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE) Muller, A.
22 S3 p. S602-S603
 artikel
958 PDG1 RECOMBINANT HUMAN ERYTHROPOIETIN VERSUS PLACEBO OR NO TREATMENT IN PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Kurylev, A.
22 S3 p. S597
 artikel
959 PDG38 RELATIONSHIP BETWEEN RELIGIOSITY-SPIRITUALITY AND MEDICATION ADHERENCE AMONG PATIENTS WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW Mohamed Ibrahim, M.I.
22 S3 p. S603
 artikel
960 PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD Gorkavenko, F.
22 S3 p. S615
 artikel
961 PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA) Giuliani, G.
22 S3 p. S611
 artikel
962 PDG55 RISK SHARING AGREEMENT ON PRESCRIPTION DRUGS: 5 YEARS EXPERIENCE OF THE KOREA NATIONAL HEALTH INSURANCE Kim, H.
22 S3 p. S606
 artikel
963 PDG47 STATUS QUO OF PHARMACEUTICAL CARE SYSTEM IN PRIMARY HEALTH CARE INSTITUTIONS OF CHINA——A LARGE SAMPLE SURVEY ON PRIMARY HEALTH CARE INSTITUTIONS OF JANGSU PROVINCE Huang, Y.
22 S3 p. S604
 artikel
964 PDG96 SURVEY ABOUT KNOWLEDGE OF NANOMEDICINES AMONG PHARMACISTS IN UKRAINE Bilous, S.
22 S3 p. S612
 artikel
965 PDG8 SYNCHRONISING MARKET AND BRAND SHAPING ACTIVITIES: THE IMPORTANCE OF POLICY AND BRAND ALIGNMENT Colasante, W.
22 S3 p. S598
 artikel
966 PDG95 THE ANALYSIS OF FACTORS AFFECTING THE CHOICE OF ANTIVIRAL OTC MEDICINES IN THE PHARMACY OF THE ARMENIAN REPUBLIC Barseghyan, A.
22 S3 p. S612
 artikel
967 PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS Rodrigues, T.
22 S3 p. S607
 artikel
968 PDG22 THE ECONOMIC IMPACT OF SERIOUS FLUOROQUINOLONE-RELATED ADVERSE EVENTS Saarukka, L.
22 S3 p. S600
 artikel
969 PDG58 THE IMPACT OF ECONOMIC REGULATION ON EXPANSIVE DRUG LIST IN FRANCE BETWEEN 2008 AND 2018 Blein, C.
22 S3 p. S606
 artikel
970 PDG49 THE IMPACT OF FUTURE MEDICAL COSTS ON DUTCH PHARMACOECONOMIC ASSESSMENTS Ophuis, R.
22 S3 p. S604-S605
 artikel
971 PDG65 THE IMPACT OF OUT-OF-POCKET SPENDING ON THE PENETRATION OF GENERIC DRUGS AFTER THE EXPIRY OF THE MARKET EXCLUSIVITY Cioni, L.
22 S3 p. S607
 artikel
972 PDG59 THE IMPACT OF TEMPORARY AUTHORIZATION USE (ATU) DOSSIER IN FRANCE SINCE THE CREATION OF FFIP (PHARMACEUTICAL INNOVATION FINANCING FUND) IN 2017 Blein, C.
22 S3 p. S606
 artikel
973 PDG4 TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON Gaarn Du Jardin, K.
22 S3 p. S597
 artikel
974 PDG9 TRANSCON TECHNOLOGY: SOLVING UNMET NEED. VALIDATION IN PEDIATRIC GROWTH HORMONE DEFICIENCY Smith, A.
22 S3 p. S598
 artikel
975 PDG34 TRENDS IN ANTIEPILEPTIC DRUG USE IN CHILDREN AND ADOLESCENTS IN IVORY COAST: AN ESTIMATE BASED ON DATA FROM A MUTUAL HEALTH INSURANCE COMPANY Kouame, J.
22 S3 p. S602
 artikel
976 PDG101 TRENDS IN PRICES AND CONSUMPTION OF BRANDED AND GENERIC OR BIOSIMILAR ANTINEOPLASTIC MEDICINES USED FOR SOLID TUMORS TREATMENT IN THE RUSSIAN PHARMACEUTICAL MARKET Nikitina, A.
22 S3 p. S613-S614
 artikel
977 PDG64 TRENDS IN THE USE OF LIPID-LOWERING DRUGS IN IVORY COAST (2017-2018) Kouame, J.
22 S3 p. S607
 artikel
978 PDG75 TRENDS IN THE USE OF PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS ARRANGEMENTS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) Hall, D.
22 S3 p. S609
 artikel
979 PDG85 TRUST THE EXPERTS? ACCEPTANCE OF EXPERT ELICITATION IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) SINGLE TECHNOLOGY APPRAISAL (STA) PROCESS van Hest, N.
22 S3 p. S611
 artikel
980 PDG68 USE OF ANTICANCER DRUGS IN IVORY COAST FROM 2017 TO 2018 Kouame, J.
22 S3 p. S608
 artikel
981 PDG97 VEMURAFENIB INDUCED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS): A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE Ravindra Reddy, N.
22 S3 p. S613
 artikel
982 PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS? Thomas, M.
22 S3 p. S610
 artikel
983 PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION Kwon, T.
22 S3 p. S604
 artikel
984 PGI26 A BUDGET IMPACT ANALYSIS OF RIFAXIMIN FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN TERTIARY HOSPITAL,RIYADH, SAUDI ARABIA Alhawwashi, S.
22 S3 p. S621
 artikel
985 PGI11 A BUDGET IMPACT MODEL FOR MEDICATION REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE PATIENTS TREATED WITH LAPAROSCOPIC NISSEN FUNDOPLICATION OR MAGNETIC SPHINCTER AUGMENTATION: AN ITALIAN PAYER PERSPECTIVE Weickum, J.
22 S3 p. S618
 artikel
986 PGI41 A MULTIPLE CRITERIA DECISION ANALYSIS OF DARVADSTROCEL VERSUS STANDARD OF CARE FOR THE TREATMENT OF COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE Athanasakis, K.
22 S3 p. S623
 artikel
987 PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM Diamantopoulos, A.
22 S3 p. S621
 artikel
988 PGI53 A QUALITATIVE STUDY EXPLORING THE BURDEN OF ULCERATIVE COLITIS AMONG CHILD, ADOLESCENT, AND ADULT PATIENTS Randall, J.A.
22 S3 p. S625-S626
 artikel
989 PGI18 ASSESSMENT OF MEDICAL COSTS ASSOCIATED WITH CROHN'S DISEASE: A TARGETED LITERATURE REVIEW Gaur, T.
22 S3 p. S619
 artikel
990 PGI38 ASSESSMENT OF PROPULSIVES CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD Iakovlieva, L.
22 S3 p. S623
 artikel
991 PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA Ghiani, M.
22 S3 p. S626-S627
 artikel
992 PGI4 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LeReun, C.
22 S3 p. S616
 artikel
993 PGI1 BAYESIAN NETWORK ANALYSIS OF MEDICARE PATIENTS WITH C-DIFF Krebsbach, C.
22 S3 p. S616
 artikel
994 PGI49 CHANGES IN HEALTH RELATED QUALITY OF LIFE IN CROHN'S DISEASE PATIENTS FOLLOWING MINDFULNESS-BASED COGNITIVE INTERVENTION: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL Sergienko, R.
22 S3 p. S625
 artikel
995 PGI25 CLINIC AND ECONOMIC ANALYSIS FOR DIAGNISIS AND TREATMENT OF DIFFICULT BILE DUCT STONES WITH SINGEL OPERATOR CHOLANGIISCOPY IN TURKEY Kockaya, G.
22 S3 p. S620-S621
 artikel
996 PGI5 COLECTOMY FOR ULCERATIVE COLITIS IN THE UK: A REVIEW OF INCIDENCE AND COMPLICATIONS Diamantopoulos, A.
22 S3 p. S616-S617
 artikel
997 PGI19 COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE Vellopoulou, K.
22 S3 p. S619-S620
 artikel
998 PGI9 COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY Quon, P.
22 S3 p. S617
 artikel
999 PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN Menchén, L.
22 S3 p. S619
 artikel
1000 PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN Taxonera, C.
22 S3 p. S619
 artikel
                             2413 gevonden resultaten
 
   volgende >>
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland